Renal Tubular Acidosis
Renal tubular acidosis is a group of disorders characterized by normal anion gap (hyperchloremic) metabolic acidosis resulting from defective renal tubular acid secretion or bicarbonate reabsorption despite relatively preserved glomerular filtration.
Renal Tubular Acidosis (RTA)
Renal Tubular Acidosis (RTA) — let's break the name down:
- "Renal" = kidney
- "Tubular" = involving the renal tubules (as opposed to the glomerulus)
- "Acidosis" = accumulation of acid (H⁺) in the body / loss of base (HCO₃⁻)
RTA is a group of disorders characterised by a normal anion gap (hyperchloraemic) metabolic acidosis caused by defective renal tubular handling of H⁺ or HCO₃⁻, in the setting of a relatively preserved glomerular filtration rate (GFR). This last point is crucial: the term RTA is reserved for patients whose kidneys are otherwise functioning well enough that the GFR alone does not explain the acidosis — distinguishing RTA from the metabolic acidosis of advanced CKD [1][2].
Key Distinction — RTA vs CKD Acidosis
Although a metabolic acidosis also occurs in those with chronic kidney disease, the term RTA is reserved for individuals with poor urinary acidification in otherwise well-functioning kidneys. [2] In CKD, the acidosis is explained by global loss of nephron mass and reduced ammoniagenesis; in RTA, there is a specific tubular defect with disproportionately preserved GFR.
There are four classical types (Types 1–4), each arising from a distinct tubular segment and pathophysiological mechanism. Type 3 is extremely rare (mixed) and often not examined separately.
Epidemiology and Risk Factors
- RTA is relatively uncommon overall but is an important cause of unexplained normal anion gap metabolic acidosis (NAGMA), especially in patients with:
- Autoimmune diseases (Sjögren syndrome, SLE) — particularly Type 1
- Diabetes mellitus — particularly Type 4 (the most common RTA overall)
- Drug exposures (e.g., lithium, amphotericin B, tenofovir disoproxil fumarate [TDF])
- Inherited metabolic diseases in children (cystinosis, Wilson's disease → Fanconi syndrome → Type 2)
- Type 1 (Distal): Bimodal — can present in infancy (hereditary forms) or in young-to-middle-aged adults (autoimmune). Classic presentation is a young lady with multiple episodes of renal nephrocalcinosis or stones → found to have low potassium, normal anion gap renal tubular acidosis → diagnosis of SLE or Sjögren's made. [1][3]
- Type 2 (Proximal): Children (inherited causes, Fanconi syndrome); adults (multiple myeloma, tenofovir)
- Type 4 (Hyperkalaemic): Older adults with diabetic nephropathy (hyporeninaemic hypoaldosteronism), CKD, or on ACEi/ARBs — this is by far the most prevalent type
- High prevalence of chronic hepatitis B → widespread use of tenofovir (TDF) → risk of acquired Fanconi syndrome (proximal RTA / Type 2) [4]
- High prevalence of diabetes mellitus → Type 4 RTA (diabetic nephropathy with hyporeninaemic hypoaldosteronism) is extremely common
- Autoimmune disease associations (SLE, Sjögren's) are not uncommon in the Hong Kong population
Anatomy and Physiology: Normal Renal Acid–Base Handling
To understand RTA, you must first understand how the kidney normally maintains acid–base balance. The kidney has two major tasks:
- Reabsorb all filtered bicarbonate (HCO₃⁻) — this happens predominantly in the proximal tubule
- Excrete the daily acid load (~1 mmol/kg/day of non-volatile acid) — this happens predominantly in the distal nephron (collecting duct)
- ~85% of filtered HCO₃⁻ (roughly 4,320 mmol/day) is reabsorbed here
- Mechanism:
- Luminal Na⁺/H⁺ exchanger (NHE3) secretes H⁺ into the lumen
- H⁺ combines with filtered HCO₃⁻ → H₂CO₃ → CO₂ + H₂O (catalysed by luminal carbonic anhydrase IV)
- CO₂ diffuses into the cell → intracellular carbonic anhydrase II converts CO₂ + H₂O → H₂CO₃ → H⁺ + HCO₃⁻
- HCO₃⁻ exits basolaterally via Na⁺/HCO₃⁻ cotransporter (NBCe1)
- The H⁺ is recycled back to the lumen via NHE3
The proximal tubule does not generate new bicarbonate — it merely reclaims what was filtered. Think of it as preventing bicarbonate from being wasted in the urine.
- Reabsorbs the remaining ~10–15% of filtered HCO₃⁻
- Also important for K⁺, Na⁺, Cl⁻, Ca²⁺, and Mg²⁺ reabsorption (relevant to Bartter syndrome)
This is where the kidney actually excretes the daily acid load and generates new HCO₃⁻ to replace that consumed by daily metabolism.
-
α-intercalated cells in the cortical and medullary collecting duct:
- Apical (luminal) H⁺-ATPase pump actively secretes H⁺ against a steep concentration gradient (can achieve urine pH as low as 4.5, i.e., a 1000:1 gradient)
- Apical H⁺/K⁺-ATPase also secretes H⁺ (and reabsorbs K⁺)
- Basolateral Cl⁻/HCO₃⁻ exchanger (AE1, band 3) exports the newly generated HCO₃⁻ into the blood
-
The secreted H⁺ is buffered in the lumen by:
- Ammonia (NH₃) → combines with H⁺ to form NH₄⁺ (ammonium) — this is the major urinary buffer
- Titratable acid — mainly phosphate (HPO₄²⁻ + H⁺ → H₂PO₄⁻)
-
Net acid excretion (NAE) = NH₄⁺ excretion + titratable acid − urinary HCO₃⁻
Each H⁺ secreted and buffered in the lumen corresponds to one new HCO₃⁻ molecule generated and returned to the blood. This is how the kidney replenishes the bicarbonate consumed by the daily metabolic acid load.
- Principal cells in the collecting duct respond to aldosterone:
- Aldosterone stimulates ENaC (epithelial Na⁺ channel) → Na⁺ reabsorption → creates a lumen-negative transepithelial voltage
- This lumen-negative voltage drives K⁺ secretion (via ROMK) and H⁺ secretion (by α-intercalated cells)
- Aldosterone also directly upregulates H⁺-ATPase on α-intercalated cells
This is why aldosterone deficiency or resistance (Type 4 RTA) causes both hyperkalaemia (reduced K⁺ secretion) and acidosis (reduced H⁺ secretion).
- NH₃/NH₄⁺ is produced in the proximal tubule from glutamine
- Transported through the medullary interstitium and secreted into the collecting duct lumen
- Hyperkalaemia directly inhibits renal ammoniagenesis and NH₄⁺ transport → this is the mechanism by which Type 4 RTA causes acidosis
Etiology and Pathophysiology (by Type)
| Feature | Type 1 (Distal) | Type 2 (Proximal) | Type 4 (Generalised) |
|---|---|---|---|
| Defect | Failure to secrete H⁺ in distal nephron | Failure to reabsorb HCO₃⁻ in proximal tubule | Aldosterone deficiency or resistance |
| Serum K⁺ | Severe hypokalaemia | Mild hypokalaemia | Hyperkalaemia |
| Urine pH | > 5.5 (always) | < 5.5 without Tx; > 6 with alkali Tx | < 5.5 |
| Nephrocalcinosis/stones | Yes (common) | Rarely | No |
| Serum HCO₃⁻ | Can be very low (< 10) | Moderate (12–20), self-limiting | Mild (17–22) |
Type 1 — Distal RTA
Inability to excrete H⁺, due to: [1]
- H⁺/ATPase pump defect → failure to pump H⁺ against concentration gradient
- Increased H⁺ permeability → H⁺ back leak (e.g., amphotericin B creates pores in the luminal membrane)
Because the α-intercalated cells cannot acidify the urine, the urine pH remains inappropriately alkaline (> 5.5) even in the setting of systemic acidosis. Normally, in acidosis the kidney should drop the urine pH to < 5.3.
Why hypokalaemia?
- Reduced H⁺ excretion → increased K⁺ excretion for exchange of Na⁺ reabsorption in distal tubule → hypokalaemia [1]
- In other words: the body still needs to maintain electrical neutrality. Na⁺ is being reabsorbed through ENaC, creating a lumen-negative voltage. Normally, this drives both H⁺ and K⁺ secretion. If H⁺ cannot be secreted, K⁺ bears the full burden → severe hypokalaemia.
Why nephrocalcinosis and renal stones? Acidosis causes: [1]
- Increased calcium resorption from bone (H⁺ is buffered by bone mineral → releases Ca²⁺ and PO₄³⁻)
- Reduced tubular Ca²⁺/PO₄ reabsorption
- Results in hypercalciuria → formation of nephrocalcinosis/stones
- Alkaline urine pH → decreased solubility of calcium phosphate → precipitation
- Reduced urinary citrate (citrate is a natural inhibitor of stone formation; acidosis promotes proximal tubular reabsorption of citrate → hypocitraturia)
Stones in Distal vs Proximal RTA — High Yield Differentiator
Proximal RTA → hypercitraturia prevents formation of renal stones. Distal RTA → hypercalciuria and hypocitraturia permit formation of nephrocalcinosis/stones. [1] This is a key clinical and exam differentiator.
Inherited (primary):
- Mutations in H⁺-ATPase subunits (ATP6V1B1, ATP6V0A4) — autosomal recessive, may be associated with sensorineural deafness
- Mutations in AE1 (Cl⁻/HCO₃⁻ exchanger, SLC4A1) — autosomal dominant or recessive
Acquired (secondary) — more relevant in HK clinical practice:
- Autoimmune diseases: Sjögren syndrome, SLE, RA [1][3]
- Sjögren syndrome is the most classic autoimmune association — lymphocytic infiltration of the renal interstitium damages the distal tubular cells
- Drugs: amphotericin B (creates membrane pores → H⁺ back-leak), lithium, ifosfamide, toluene
- Hypercalcaemia / nephrocalcinosis (e.g., primary hyperparathyroidism, sarcoidosis) — calcium deposition damages distal tubular cells, creating a vicious cycle
- Chronic obstructive uropathy
- Medullary sponge kidney
Autoimmune Association — Must Know
When approaching any case of distal renal tubular acidosis, you must keep in mind autoimmune causes such as Sjögren's and SLE. [1] Be very careful though — Sjögren's can also cause proximal RTA [1] (though distal is far more common). A young woman with recurrent nephrocalcinosis + hypokalaemia + NAGMA should prompt screening for autoimmune disease.
Type 2 — Proximal RTA
Reduced HCO₃⁻ reabsorption threshold in the proximal tubules. [1]
Normally, the proximal tubule reabsorbs virtually all filtered HCO₃⁻ up to a renal threshold (Tm) of ~26–28 mmol/L. In Type 2 RTA, this threshold is reduced to ~15–20 mmol/L [5].
The key insight is that proximal RTA is self-regulating: [5]
If plasma [HCO₃⁻] > Tm → urinary HCO₃⁻ loss → plasma [HCO₃⁻] falls
If plasma [HCO₃⁻] < Tm → distal mechanism generates HCO₃⁻ by excreting extra H⁺ → plasma [HCO₃⁻] rises back to TmTherefore, plasma [HCO₃⁻] stabilises at the new, lower Tm (typically 12–20 mmol/L). The acidosis is moderate and self-limiting — it does not progress to severely low levels as in distal RTA.
Urine pH is variable: [5]
- Without bicarbonate treatment: plasma [HCO₃⁻] = Tm, so urinary bicarbonate excretion is actually minimal and the distal nephron functions normally to acidify urine → urine pH usually ≤ 5.3
- With bicarbonate treatment: plasma [HCO₃⁻] > Tm → massive urinary bicarbonate loss → urine pH inappropriately > 6
- This is a key differentiator from Type 1 (where urine pH is always > 5.5 regardless of treatment)
Why mild hypokalaemia? [5]
- Without treatment: metabolic acidosis → slightly diminished proximal Na⁺ reabsorption → modest hypovolaemia → secondary hyperaldosteronism → modest hypokalaemia
- With bicarbonate treatment: this is where the problem worsens — increased urinary HCO₃⁻ loss → increased Na⁺ loss (Na⁺ and HCO₃⁻ are co-transported) → increased distal delivery of Na⁺/water and HCO₃⁻ (an impermeant anion that enhances the lumen-negative voltage) → marked K⁺ secretion → worsening hypokalaemia
Alkali Treatment Paradox in Type 2 RTA
Effect of alkali treatment on K⁺: [3]
- Type 1: improves K⁺ — alkaline urine allows increased H⁺ excretion, expands ECV and reduces Na⁺ reabsorption pressure
- Type 2: worsens K⁺ — increased distal Na⁺ delivery causes increased K⁺ secretion
This is a commonly tested exam concept. Giving bicarbonate to a patient with proximal RTA can make them more hypokalaemic.
The proximal tubule reabsorbs many substances besides HCO₃⁻. When there is a generalised proximal tubular dysfunction, you get Fanconi syndrome:
Fanconi syndrome: generalised proximal tubule dysfunction → decreased reabsorption of amino acids, glucose, PO₄, bicarbonate, Na, Ca, K, Mg. [6][7]
Clinical features of Fanconi syndrome:
- Polyuria, polydipsia (decreased water reabsorption) [6]
- Salt depletion and dehydration (decreased Na, water) [6]
- Hyperchloraemic metabolic acidosis (decreased bicarbonate reabsorption) [6]
- Rickets in children / osteomalacia in adults (decreased Ca, PO₄ → hypophosphataemia) [6]
- Poor growth [6]
- Glycosuria (without diabetes — glucose in urine with normal blood glucose)
- Aminoaciduria (generalised, non-specific)
- Tubular (low molecular weight) proteinuria
- Hyperuricosuria with hypouricaemia
- Hypercitraturia (this actually protects against stone formation — contrast with Type 1!)
Inherited: [6]
- Cystinosis (most common inherited cause in children)
- Glycogen storage disorders
- Lowe syndrome (oculocerebrorenal dystrophy — X-linked: vision problems, kidney problems, brain anomalies) [6]
- Galactosaemia, fructose intolerance, tyrosinaemia
- Wilson's disease
- Drugs/toxins:
- Tenofovir disoproxil fumarate (TDF) — TDF is associated with proximal renal tubulopathy, hypophosphataemia, osteomalacia, and acquired Fanconi syndrome [4]. TAF (tenofovir alafenamide) is preferred because it achieves lower circulating tenofovir levels (> 90% reduction) with equivalent antiviral potency [4]
- Ifosfamide, cisplatin (→ tubular diseases resulting in hypokalaemia and hypomagnesaemia [8])
- Gentamicin, amphotericin B [6]
- Valproic acid, expired tetracyclines
- Heavy metals (lead, cadmium, mercury) [6]
- Monoclonal gammopathy / multiple myeloma — light chains are directly toxic to proximal tubular cells [3]
- Amyloidosis
When to Suspect Renal Tubular Problems — GC Lecture High Yield
Severe and multiple electrolyte abnormalities (e.g., severe hypoK + hypoPO₄ → RTA) [9]
Unusual combination of acid-base and electrolyte abnormalities: [9]
- Usual situation: hypoK + metabolic alkalosis OR hyperK + metabolic acidosis
- If hypoK + metabolic acidosis: ? RTA
Presence of unusual substance in urine: glucose (without DM), amino acids [9]
Other clinical associations: e.g., Sjögren's syndrome with distal RTA [9]
- Extremely rare; features of both Type 1 and Type 2
- Seen almost exclusively in inherited conditions (carbonic anhydrase II deficiency — autosomal recessive)
- Associated with osteopetrosis, cerebral calcification, intellectual disability
- Not commonly examined; mentioned for completeness
Type 4 — Hyperkalaemic RTA
Decreased aldosterone secretion or effect → increased K⁺ → decreased NH₄⁺ excretion [3]
This is the only type of RTA associated with hyperkalaemia. The mechanism has two components:
-
Reduced K⁺ secretion: Aldosterone normally stimulates ENaC-mediated Na⁺ reabsorption and K⁺ secretion via ROMK. Without aldosterone action → hyperkalaemia.
-
Reduced H⁺ excretion: Via two mechanisms:
- Aldosterone directly stimulates H⁺-ATPase on α-intercalated cells → loss of this stimulus → reduced H⁺ secretion
- Hyperkalaemia itself inhibits renal ammoniagenesis (NH₃ production from glutamine in the proximal tubule) and inhibits NH₄⁺ transport in the medullary thick ascending limb → reduced NH₄⁺ available for buffering in the collecting duct → reduced net acid excretion → acidosis
The acidosis is typically mild (HCO₃⁻ 17–22 mmol/L) because the ability to lower urine pH is preserved (the H⁺-ATPase can still function, just less efficiently). Urine pH < 5.5 [3].
Aldosterone deficiency:
- Hyporeninaemic hypoaldosteronism — the most common cause overall, typically seen in diabetic nephropathy [2][3]
- Diabetic nephropathy damages the juxtaglomerular apparatus → reduced renin → reduced angiotensin II → reduced aldosterone
- Addison's disease (primary adrenal insufficiency) [3]
- Congenital adrenal hyperplasia (CAH) [3]
- Heparin (inhibits aldosterone synthesis)
- Ketoconazole
Aldosterone resistance:
- Calcineurin inhibitors (CNI) — cyclosporin, tacrolimus [3]
- ACEi / ARBs (block RAS → reduced aldosterone) [3]
- Potassium-sparing diuretics (spironolactone, amiloride, triamterene)
- Trimethoprim (blocks ENaC — mimics amiloride)
- Pseudohypoaldosteronism (inherited ENaC mutations)
Diabetes and Type 4 RTA — High Yield
Diabetes is associated with Type IV renal tubular acidosis — cannot excrete potassium. [2] This is extremely common and clinically relevant. A diabetic patient on ACEi/ARB presenting with persistent hyperkalaemia and mild metabolic acidosis likely has Type 4 RTA. Do not simply attribute the hyperkalaemia to ACEi alone — there is often an underlying hyporeninaemic hypoaldosteronism from diabetic nephropathy.
Clinical Features
The symptoms of RTA are largely non-specific and relate to the consequences of chronic metabolic acidosis, electrolyte disturbances, and any underlying cause.
| Symptom | Mechanism | Type(s) |
|---|---|---|
| Fatigue, malaise, weakness | Chronic metabolic acidosis impairs cellular metabolism; hypokalaemia causes muscle weakness (K⁺ is critical for resting membrane potential of muscle cells — low K⁺ hyperpolarises the cell, making it harder to depolarise and contract) | All |
| Polyuria and polydipsia | Hypokalaemia impairs renal concentrating ability (downregulates AQP2 in collecting duct, causes resistance to ADH → nephrogenic DI-like picture); also osmotic diuresis from bicarbonaturia in Type 2 | Types 1, 2 |
| Nausea, vomiting, anorexia | Chronic metabolic acidosis; may also relate to underlying disease | All |
| Muscle cramps / tetany | Severe hypokalaemia; or associated hypocalcaemia (especially if concurrent vitamin D deficiency / rickets) | Types 1, 2 |
| Palpitations | Hypokalaemia → cardiac arrhythmias (U waves, prolonged QT, risk of torsades de pointes); or hyperkalaemia → peaked T waves, bradycardia, VF in Type 4 | All |
| Bone pain | Chronic acidosis → bone mineral dissolution (buffering of H⁺ by bone CaCO₃/CaPO₄) → osteomalacia/rickets | Types 1, 2 |
| Flank pain / renal colic | Nephrocalcinosis and calcium phosphate stone formation | Type 1 |
| Growth failure / failure to thrive (children) | Chronic acidosis impairs growth hormone axis, reduces protein synthesis, promotes catabolism; also hypophosphataemia impairs mineralisation | Types 1, 2 |
| Recurrent UTIs | Nephrocalcinosis acts as a nidus for infection; structural abnormalities | Type 1 |
| Sign | Mechanism | Type(s) |
|---|---|---|
| Short stature (children) | Chronic metabolic acidosis + rickets (discussed above) | Types 1, 2 |
| Kussmaul breathing (deep, rapid) | Respiratory compensation for metabolic acidosis — the brainstem chemoreceptors detect low pH → stimulate ventilation to blow off CO₂ | All (more prominent with severe acidosis) |
| Muscle hypotonia / hyporeflexia | Hypokalaemia → hyperpolarisation of neuromuscular junction | Types 1, 2 |
| Rachitic / osteomalacic bone deformities | Rickets (children): widened wrists, bowing of legs, rachitic rosary. Osteomalacia (adults): bone tenderness, proximal myopathy, waddling gait. Caused by phosphate wasting (Fanconi) and chronic acidosis-induced bone mineral loss | Types 1, 2 |
| Nephrocalcinosis (on imaging — KUB or USS) | Calcium phosphate precipitation in alkaline urine + hypercalciuria + hypocitraturia | Type 1 |
| Signs of underlying disease | Dry eyes/mouth (Sjögren's), malar rash (SLE), parotid enlargement (Sjögren's) | Type 1 especially |
| Ileus / abdominal distension | Severe hypokalaemia → smooth muscle paralysis → paralytic ileus | Types 1, 2 |
| ECG changes | HypoK: flattened T waves, U waves, ST depression, prolonged QT. HyperK: peaked T waves, widened QRS, sine wave | Types 1,2 (hypoK) / Type 4 (hyperK) |
| Hypertension or hypotension | Type 4 with Addison's → hypotension. Type 4 with diabetic nephropathy → often hypertensive | Type 4 |
Pathophysiological Basis of Key Clinical Features — Explained from First Principles
In Type 1, the collecting duct cannot secrete H⁺ at all. Na⁺ is still being reabsorbed through ENaC under aldosterone influence, generating a lumen-negative voltage. This voltage must be balanced by cation secretion. Since H⁺ cannot be secreted, K⁺ bears the entire electrical burden → severe K⁺ wasting → severe hypokalaemia.
In Type 2, the distal nephron is intact. The distal H⁺ secretion mechanism works fine. The K⁺ loss is modest and mainly driven by secondary hyperaldosteronism (from mild volume depletion) and increased distal Na⁺ delivery. The hypokalaemia is mild unless bicarbonate therapy is given (which dramatically increases distal Na⁺ and HCO₃⁻ delivery → worsening K⁺ loss) [5].
Type 1:
- Alkaline urine (pH > 5.5) → calcium phosphate is less soluble at higher pH → precipitation
- Chronic acidosis → bone buffering → hypercalciuria
- Acidosis → increased proximal citrate reabsorption → hypocitraturia (citrate normally inhibits crystallisation)
- Triple hit: alkaline urine + hypercalciuria + hypocitraturia = stones/nephrocalcinosis
Type 2:
- Urine pH is not consistently alkaline (urine can be acidified when plasma HCO₃⁻ is at steady state)
- Hypercitraturia (PCT dysfunction → impaired citrate reabsorption → more citrate in urine → protects against stone formation) [1]
- Aminoaciduria (amino acids also inhibit crystallisation)
- Therefore, stones are rare in proximal RTA [1]
Types 1 and 2 involve defects in H⁺ handling or HCO₃⁻ reclamation — neither directly impairs K⁺ secretion (and in fact, compensatory mechanisms increase K⁺ loss). In Type 4, the fundamental problem is aldosterone deficiency or resistance, which directly reduces K⁺ secretion through the principal cells' ROMK channels. Additionally, the resultant hyperkalaemia itself suppresses ammoniagenesis (the ammonia production pathway in the proximal tubule is inhibited by high K⁺), reducing the kidney's ability to buffer secreted H⁺ → worsening acidosis.
| Clue | Type 1 | Type 2 | Type 4 |
|---|---|---|---|
| Anion gap | Normal | Normal | Normal |
| Serum K⁺ | ↓↓ | ↓ | ↑ |
| Urine pH (untreated) | > 5.5 | < 5.5 | < 5.5 |
| Urine pH (with alkali Tx) | > 5.5 | > 6 | N/A |
| FE(HCO₃⁻) with alkali loading | < 5% | > 15% [3] | < 5% |
| Nephrocalcinosis/stones | Yes | Rarely | No |
| Fanconi features | No | Often | No |
| Urine anion gap | Positive | Positive/Negative | Positive |
| Gold standard Ix | NH₄Cl loading test: urine pH remains high & UAG inappropriately +ve [3] | Bicarbonate loading test: FEHCO₃ > 15%; urine glucose, amino acids [3] | TTKG < 7; renin, aldosterone, cortisol [3] |
High Yield Summary
-
RTA = normal anion gap (hyperchloraemic) metabolic acidosis with relatively preserved GFR, caused by specific tubular defects in H⁺ secretion or HCO₃⁻ reclamation
-
Type 1 (Distal): Cannot secrete H⁺ → urine pH always > 5.5 → severe hypokalaemia → nephrocalcinosis/stones (hypercalciuria + hypocitraturia + alkaline urine). Think autoimmune (Sjögren's, SLE), amphotericin B
-
Type 2 (Proximal): Cannot reabsorb HCO₃⁻ → lowered Tm → self-limiting acidosis → urine pH variable (< 5.5 untreated, > 6 with alkali). Often part of Fanconi syndrome. Think TDF, myeloma, cystinosis (kids). Stones rare (hypercitraturia protects)
-
Type 4 (Hyperkalaemic): Aldosterone deficiency/resistance → hyperkalaemia → reduced ammoniagenesis → mild acidosis, urine pH < 5.5. Most common type overall. Think diabetic nephropathy (hyporeninaemic hypoaldosteronism), ACEi/ARB, Addison's
-
Suspect RTA when: hypoK + metabolic acidosis (unusual combination), severe/multiple electrolyte abnormalities, glycosuria without DM, aminoaciduria, or autoimmune disease with electrolyte disturbances
-
Alkali therapy improves K⁺ in Type 1 but worsens K⁺ in Type 2 — know why
-
Nephrocalcinosis differentiates distal from proximal RTA
Active Recall - Renal Tubular Acidosis
[1] Senior notes: Block A - Electrolyte and Acid-Base Disorders.pdf (Renal Tubular Acidosis section) [2] Senior notes: Block A – Nephrology Data Interpretation.pdf (Case interpretation, RTA definitions) [3] Senior notes: Maksim Medicine Notes.pdf (p214, RTA comparison table) [4] Senior notes: Block A - I am a hepatitis B carrier.pdf (TDF vs TAF, Fanconi syndrome) [5] Senior notes: Ryan Ho Urogenital.pdf (p42, Proximal and Distal RTA detailed pathophysiology) [6] Senior notes: Adrian Lui Pediatrics Notes.pdf (p311, Fanconi syndrome) [7] Senior notes: Block A - Nephrotology Teaching Clinic RTD.pdf (Fanconi syndrome, Type 1 RTA case) [8] Senior notes: Block A - Chronic Kidney Disease and its Complications.pdf (Cisplatin tubular toxicity) [9] Lecture slides: Introduction-kidney-Ix.pdf / Nephrology - ntroduction to Renal Investigation.pdf (p29, When to suspect renal tubular problems)
Differential Diagnosis of Renal Tubular Acidosis
When you encounter a patient whose biochemistry suggests RTA — that is, a normal anion gap (hyperchloraemic) metabolic acidosis with relatively preserved GFR — your clinical job is twofold:
- Distinguish RTA from other causes of normal anion gap metabolic acidosis (NAGMA) — because not every NAGMA is RTA
- Differentiate between the types of RTA (Types 1, 2, and 4) — because each has a different underlying cause, prognosis, and treatment
This section systematically walks through both levels of differential diagnosis.
The differential diagnosis for NAGMA broadly divides into GI bicarbonate loss vs renal causes (RTA) [3][10].
NAGMA Aetiology: [3]
- GI: diarrhoea, surgical drains / fistula, ureterosigmoidostomy
- Renal: RTA
The crucial first-line discriminating tool is the urine anion gap (UAG).
Why does the urine anion gap help?
The urine anion gap is an indirect estimate of urinary ammonium (NH₄⁺) excretion. The formula is:
UAG = Urine [Na⁺] + Urine [K⁺] − Urine [Cl⁻]
- NH₄⁺ is excreted with Cl⁻ as its accompanying anion. When the kidney appropriately increases NH₄⁺ excretion in response to acidosis (the normal response), there will be a lot of Cl⁻ in the urine → UAG becomes negative (because Cl⁻ outweighs Na⁺ + K⁺)
- If the kidney cannot excrete NH₄⁺ appropriately (as in RTA), Cl⁻ will not rise → UAG becomes positive (or inappropriately zero/slightly positive) [3][7]
| Condition | UAG | Interpretation |
|---|---|---|
| GI HCO₃⁻ loss (diarrhoea) | Negative | Kidney is working fine → compensatory ↑ NH₄⁺ excretion |
| Type 1 RTA (Distal) | Positive | Cannot secrete H⁺ → ↓ NH₄⁺ excretion [3] |
| Type 2 RTA (Proximal) | Positive or Negative | Distal acidification may be intact (negative at steady state) but can be positive [3] |
| Type 4 RTA | Positive | Hyperkalaemia → ↓ ammoniagenesis → ↓ NH₄⁺ [3] |
An alternative/complementary test is the urine osmolar gap, which more directly estimates NH₄⁺:
Urine osmolar gap = Measured urine osmolality − Calculated urine osmolality
Where calculated = 2(Urine Na⁺ + Urine K⁺) + Urine urea + Urine glucose
- Normal urine osmolar gap > 30; abnormal indicates decreased NH₄⁺ excretion [3]
GI Loss vs RTA — The Key Fork in the Road
When you see NAGMA, ask yourself: "Is the kidney responding appropriately by dumping NH₄⁺?" If yes (negative UAG), the problem is extrarenal (usually GI). If no (positive UAG), the problem is the kidney itself → RTA. This is the single most important branching point.
If positive urine anion gap — suggests normal or low excretion of ammonium ions → diagnosis of RTA. [7]
If negative urine anion gap — suggests increased excretion of ammonium ions → cause of metabolic acidosis is likely diarrhoea (GI loss of potassium). [7]
A pragmatic approach uses serum potassium as the first branch, then urine potassium and urine pH as further discriminators. This is how the HKUMed teaching frames the workup [10][11]:
Step 1: Assess plasma HCO₃⁻ and paired spot urine K⁺ before replacement [11]
| Serum K⁺ | Urine K⁺ | Diagnosis |
|---|---|---|
| Low K⁺ + Low HCO₃⁻ | > 20 mmol/L (renal loss) | Renal tubular acidosis Type 1 or 2 [10][11] |
| Low K⁺ + Low HCO₃⁻ | < 20 mmol/L (extrarenal loss) | Acute diarrhoea [10][11] |
| Low K⁺ + Normal/High HCO₃⁻ | > 20 mmol/L | Vomiting, Conn's, diuretics, Mg²⁺ depletion, leukaemia |
| Low K⁺ + Normal/High HCO₃⁻ | < 20 mmol/L | Chronic diarrhoea, laxative abuse, previous diuretics, inadequate intake, transcellular shift |
| High K⁺ + Low HCO₃⁻ | — | Type 4 RTA, or advanced CKD [1] |
High Yield — GC Lecture Slide Point
Hypokalemic acidosis is unusual — it immediately alerts you to several differential diagnoses, specifically normal AG acidosis: [1]
- Proximal RTA (Type II) → due to loss of HCO₃⁻
- Distal RTA (Type I) → due to failure of H⁺ excretion
- Mixed RTA (Type III)
Typical pattern: hypoK + metabolic alkalosis OR hyperK + metabolic acidosis. If hypoK + metabolic acidosis → ? RTA [9]
Level 2: Differentiating Between Types of RTA
Once you have established that the NAGMA is due to RTA (positive UAG, preserved GFR), the next step is to determine which type. The three clinically relevant differentials are Type 1, Type 2, and Type 4.
| Feature | Type 1 (Distal) | Type 2 (Proximal) | Type 4 (Hyperkalaemic) |
|---|---|---|---|
| Serum K⁺ | Severe hypokalaemia | Mild hypokalaemia | Hyperkalaemia [3] |
| Serum HCO₃⁻ | Can be very low (< 10 mmol/L) — severe | Moderate (12–20), self-limiting at new Tm | Mild (17–22) [3] |
| Urine pH (untreated) | > 5.5 (always) — diagnostic [3][12] | < 5.5 (distal mechanism intact at steady state) [3] | < 5.5 [3] |
| Urine pH (with alkali Tx) | Still > 5.5 | > 6 (massive bicarbonaturia) | Not routinely tested |
| UAG | Positive | Positive or Negative | Positive [3] |
| Nephrocalcinosis/stones | Yes — calcium phosphate [1][13] | Rarely (hypercitraturia protects) [1] | No |
| Fanconi features | No | Often (glycosuria, aminoaciduria, phosphaturia) | No |
| FE(HCO₃⁻) | < 5% | > 15% (diagnostic) [3][7] | < 5% |
| Gold standard confirmatory test | NH₄Cl loading test [3][12] | Bicarbonate loading test [3][7] | TTKG < 7; renin, aldo, cortisol [3] |
GC Lecture Slide — Diagnostic Suspicion Criteria
Why Each Discriminator Works — Explained from First Principles
- In Type 1 the α-intercalated cells literally cannot acidify the urine (H⁺-ATPase defect or back-leak), so urine pH remains > 5.5 at all times regardless of systemic acidosis [1]. This is the single most useful bedside discriminator.
- In Type 2, the distal nephron is intact. At steady state (when plasma HCO₃⁻ has already fallen to the new Tm), there is no excess HCO₃⁻ reaching the distal nephron, so the distal H⁺ secretion mechanism can acidify the urine normally → urine pH < 5.5 when untreated [1][5]. The pH only rises when you give bicarbonate and push plasma HCO₃⁻ above the lowered Tm, flooding the distal nephron with HCO₃⁻ it cannot handle.
- In Type 4, the collecting duct H⁺-ATPase can still function (just suboptimally) → urine pH usually < 5.5 [3].
This is explained by the fundamentally different defects. Types 1 and 2 involve H⁺ or HCO₃⁻ handling defects, which secondarily increase K⁺ wasting. Type 4 involves aldosterone deficiency/resistance, which directly impairs K⁺ secretion.
Presence or absence of renal stones can differentiate proximal and distal RTA: [1]
- Distal RTA → hypercalciuria + alkaline urine + hypocitraturia permits stone formation
- Proximal RTA → hypercitraturia prevents stone formation
This is a favourite exam discriminator. RTA Type I (Distal) is listed as a risk factor for formation of calcium stones [13].
This is the confirmatory test for Type 2 RTA. You infuse IV sodium bicarbonate to raise plasma HCO₃⁻ above the lowered Tm. Then you measure how much bicarbonate spills into the urine:
FE(HCO₃⁻) = (Urine HCO₃⁻ × Plasma creatinine) / (Plasma HCO₃⁻ × Urine creatinine) × 100%
This is the gold standard for Type 1 RTA. You give oral NH₄Cl to create an exogenous acid load. In a normal person, the kidney responds by acidifying the urine to pH < 5.3. In Type 1 RTA:
- Urine pH remains high (> 5.5) and UAG remains inappropriately positive — the kidney simply cannot mount the H⁺ secretion response [3]
Used in Type 4 RTA to assess whether aldosterone is functioning:
- TTKG < 7 suggests aldosterone deficiency/resistance [3] — because aldosterone normally drives K⁺ secretion in the cortical collecting duct; without it, the K⁺ gradient is low
- Follow up with renin, aldosterone, and cortisol levels to determine the exact aetiology (hyporeninaemic hypoaldosteronism vs primary adrenal insufficiency vs drug-induced)
Differential Diagnosis of Underlying Causes (Within Each RTA Type)
Once you have established the type of RTA, you then need to determine the underlying cause. The differentials within each type are clinically important:
| Category | Examples | Clues |
|---|---|---|
| Autoimmune | Sjögren syndrome, SLE, RA [1][3] | Dry eyes/mouth (Sjögren), malar rash (SLE), joint symptoms; anti-Ro/La, ANA, dsDNA |
| Drugs | Amphotericin B [3], lithium, ifosfamide, toluene | Drug history; toluene = glue-sniffing |
| Hypercalcaemia | Primary hyperparathyroidism [3], sarcoidosis | Elevated Ca²⁺, PTH; medullary nephrocalcinosis |
| Genetic | H⁺-ATPase mutations, AE1 mutations | Infantile onset, sensorineural deafness (ATP6V1B1) |
| Structural | Medullary sponge kidney, chronic obstruction | USS findings |
| Category | Examples | Clues |
|---|---|---|
| Isolated HCO₃⁻ wasting | Carbonic anhydrase inhibitors (acetazolamide), topiramate | Drug history |
| Fanconi syndrome — inherited | Cystinosis, Wilson's disease, galactosaemia, fructose intolerance, tyrosinaemia, Lowe syndrome, glycogen storage diseases [6] | Paediatric onset, FHx, specific IEM features (Kayser-Fleischer rings for Wilson's) |
| Fanconi syndrome — acquired | TDF [4], cisplatin, ifosfamide, aminoglycosides, heavy metals | Drug/toxin exposure; TDF → Fanconi syndrome: osteomalacia, hyperphosphaturia, hypophosphataemia [4] |
| Monoclonal gammopathy / myeloma [3] | Light chain deposition | Elderly, bone pain, raised globulin, M-band on SPEP |
| Amyloidosis | AL amyloidosis | Proteinuria, organomegaly |
| Category | Examples | Clues |
|---|---|---|
| Hyporeninaemic hypoaldosteronism | Diabetic nephropathy [2][3] | Long-standing DM, mild CKD, disproportionate hyperkalaemia |
| Primary adrenal insufficiency | Addison's disease, CAH [3] | Hypotension, hyperpigmentation, hyponatraemia, cortisol deficiency |
| Drugs | ACEi/ARB [3], calcineurin inhibitors (CNI) [3], K⁺-sparing diuretics, trimethoprim, heparin | Drug history is everything |
| Pseudohypoaldosteronism | ENaC mutations | Rare, neonatal presentation |
| Obstructive uropathy | Bilateral obstruction | USS: hydronephrosis |
When Investigating Conn's Syndrome — Must Exclude RTA
When investigating for Conn's syndrome (primary aldosteronism), exclude other causes of hypokalaemia first: [14]
- Diuretics
- GI loss
- Renal tubular acidosis (Type 1 to 3)
This is clinically important — do not chase a Conn's diagnosis before ruling out RTA as the cause of hypokalaemia.
Several conditions can mimic certain features of RTA and must be kept in the differential:
| Mimic | Shared Features | How to Distinguish |
|---|---|---|
| CKD-associated acidosis | NAGMA, hyperK (like Type 4) | GFR is markedly reduced in CKD; RTA by definition has relatively preserved GFR |
| Diarrhoea | NAGMA, hypoK (like Type 1/2) | UAG is negative (appropriate renal NH₄⁺ response); clinical history of diarrhoea |
| Ureterosigmoidostomy | NAGMA, hypoK | Cl⁻/HCO₃⁻ exchange across colonic mucosa; surgical history is diagnostic |
| Bartter syndrome | HypoK, metabolic derangement | Metabolic alkalosis (not acidosis); mimics loop diuretic use; hypoMg, hypoCl [7] |
| Gitelman syndrome | HypoK, metabolic derangement | Metabolic alkalosis (not acidosis); mimics thiazide diuretic use; hypoMg, hypocalciuria [15] |
| Diuretic use | HypoK | Metabolic alkalosis (not acidosis); drug history |
| Vomiting | HypoK | Metabolic alkalosis (from H⁺/Cl⁻ loss); high urine Cl⁻ can help differentiate |
The single most important distinction: in RTA you have acidosis with hypokalaemia. In most other common causes of hypokalaemia (diuretics, vomiting, Bartter/Gitelman), you have alkalosis with hypokalaemia. The unusual combination of hypoK + metabolic acidosis is a red flag for RTA. [1][9]
From the kidney perspective, the pattern of electrolyte disturbance tells you which part of the kidney is damaged: [15]
- Glucose + acidosis → proximal tubule dysfunction (Fanconi / Type 2 RTA)
- Problems only in potassium → loop of Henle or distal tubule → Bartter syndrome, Gitelman syndrome [15]
- Acidosis + hypokalaemia → distal tubular pathology [15]
- Concentration problem → SIADH, diabetes insipidus → collecting ducts [15]
This pattern-recognition framework is extremely useful in data interpretation stations.
| Presentation | Top Differentials | Key Discriminators |
|---|---|---|
| NAGMA + hypoK + urine pH > 5.5 + nephrocalcinosis | Type 1 (Distal) RTA | Always alkaline urine; confirm with NH₄Cl loading test; screen for Sjögren/SLE |
| NAGMA + hypoK + urine pH < 5.5 + glycosuria/aminoaciduria/hypoPO₄ | Type 2 (Proximal) RTA / Fanconi | Urine pH variable; confirm with HCO₃⁻ loading (FE > 15%); look for myeloma, TDF, IEM |
| NAGMA + hyperK + urine pH < 5.5 | Type 4 RTA | TTKG < 7; check renin/aldo/cortisol; DM nephropathy, ACEi/ARB |
| NAGMA + hypoK + negative UAG | GI HCO₃⁻ loss (diarrhoea) | Appropriate renal response; clinical history |
| HypoK + metabolic alkalosis | Not RTA — diuretics, vomiting, Bartter, Gitelman, Conn's | Alkalosis, not acidosis |
| Acidosis + markedly reduced GFR | CKD acidosis | Not "RTA" by definition; GFR is the explanation |
High Yield Summary — Differential Diagnosis of RTA
-
NAGMA = GI loss vs RTA → Use UAG (negative = GI, positive = RTA) and urine K⁺ to differentiate
-
HypoK + acidosis is unusual → Think RTA Types 1 or 2. HyperK + acidosis → think Type 4 RTA or CKD
-
Urine pH is the single most useful bedside test → > 5.5 always = Type 1; < 5.5 at steady state = Type 2 or Type 4
-
Nephrocalcinosis/stones → strongly favours Type 1 over Type 2
-
Fanconi features (glycosuria, aminoaciduria, hypoPO₄) → Type 2
-
Confirmatory tests: NH₄Cl loading (Type 1), FEHCO₃⁻ > 15% (Type 2), TTKG + renin/aldo (Type 4)
-
Always look for the underlying cause: autoimmune (Types 1, 2), drugs (all types), DM nephropathy (Type 4), IEM (Type 2 in children), myeloma (Type 2 in elderly)
-
Do not confuse with Bartter/Gitelman → these cause metabolic alkalosis, not acidosis
Active Recall - Differential Diagnosis of RTA
References
[1] Senior notes: Block A - Electrolyte and Acid-Base Disorders.pdf (Renal Tubular Acidosis section) [2] Senior notes: Block A – Nephrology Data Interpretation.pdf (Case interpretation, Type 4 RTA and DM) [3] Senior notes: Maksim Medicine Notes.pdf (p214, RTA comparison table) [4] Senior notes: Block A - I am a hepatitis B carrier.pdf (TDF vs TAF, Fanconi syndrome) [5] Senior notes: Ryan Ho Urogenital.pdf (p42, Proximal and Distal RTA detailed pathophysiology) [6] Senior notes: Adrian Lui Pediatrics Notes.pdf (p311, Fanconi syndrome) [7] Senior notes: Block A - Nephrotology Teaching Clinic RTD.pdf (Fanconi syndrome, Distal RTA case, Bartter case, UAG interpretation) [9] Lecture slides: Introduction-kidney-Ix.pdf / Nephrology - ntroduction to Renal Investigation.pdf (p29, When to suspect renal tubular problems) [10] Senior notes: Ryan Ho Chemical Path.pdf (p18, Hypokalaemia workup with HCO3 and urine K) [11] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p60, Diagnostic algorithm for hypokalaemia) [12] Lecture slides: GC 044. Electrolyte and Acid-Base Disorders.pdf (p25, RTA Diagnosis slide) [13] Senior notes: MBBS Final MB (Surgery) (Felix PY Lai).pdf (p790, RTA Type I as risk factor for calcium stones) [14] Senior notes: Block A - I have fluctuating BP_ cushing syndrome; adrenal diseases and tumours; other endocrine tumours.pdf (p8, Conn's investigation — exclude RTA) [15] Senior notes: Block A - Introduction to Renal Investigations (RFT, urine tests and US kidneys).pdf (Tubular segment localisation)
Diagnostic Criteria, Algorithm, and Investigations for Renal Tubular Acidosis
RTA does not have a single "diagnostic criteria set" like, say, the SLICC criteria for SLE. Instead, the diagnosis is established through a stepwise biochemical pattern-recognition approach. Think of it as building a case from multiple converging pieces of evidence rather than ticking boxes on a checklist.
The diagnosis of RTA requires all three of the following foundational criteria to be met simultaneously:
- Normal anion gap (hyperchloraemic) metabolic acidosis — confirmed on arterial blood gas (ABG) and electrolyte panel
- Relatively preserved GFR — because if GFR is severely reduced, the acidosis is explained by uraemic acidosis (CKD), not a tubular defect. Although a metabolic acidosis also occurs in those with CKD, the term RTA is reserved for individuals with poor urinary acidification in otherwise well-functioning kidneys [2]
- Evidence of inappropriate renal acid handling — either failure to acidify urine (urine pH > 5.5 in acidaemia), failure to reabsorb bicarbonate (elevated FEHCO₃⁻), or impaired ammonium excretion (positive UAG)
GC Lecture Slide — Clinical Suspicion Criteria (High Yield)
Why "↑Cl⁻ with normal Na⁺" is a hint
The anion gap = Na⁺ − (Cl⁻ + HCO₃⁻). In NAGMA, as HCO₃⁻ drops, Cl⁻ rises to maintain electroneutrality (the Cl⁻/HCO₃⁻ exchanger in the kidney and gut drives this reciprocal relationship). So Na⁺ stays normal, but Cl⁻ is elevated — this pattern immediately signals NAGMA without even formally computing the anion gap. It is a quick bedside "eyeball" that the electrolyte and acid-base abnormalities block A notes refer to: increased serum chloride with normal sodium → normal anion gap [1].
This algorithm integrates the approach taught across the HKUMed teaching clinics, data interpretation sessions, and GC lectures. It progresses logically: confirm acidosis → classify the acidosis → locate the problem (GI vs kidney) → subtype the RTA → find the underlying cause.
Step-by-Step Walkthrough with Investigations
Investigation: Arterial Blood Gas (ABG)
| Parameter | Expected in RTA |
|---|---|
| pH | Low (< 7.35) — acidaemia |
| HCO₃⁻ | Low (primary disturbance) |
| pCO₂ | Low (respiratory compensation — the lungs blow off CO₂ to compensate, which is why you see Kussmaul breathing) |
| Base excess | Negative (metabolic acidosis) |
Metabolic acidosis: pH low, HCO₃⁻ very low (primary), pCO₂ low (compensatory) [16]
Why is pCO₂ low? — For every 1 mmol/L drop in HCO₃⁻ from normal, pCO₂ should drop by approximately 1.2 mmHg (Winter's formula: Expected pCO₂ = 1.5 × [HCO₃⁻] + 8 ± 2). If pCO₂ is higher than expected, there is a concurrent respiratory acidosis; if lower, a concurrent respiratory alkalosis.
Investigation: Electrolyte panel (RFT)
Anion Gap = [Na⁺] − [Cl⁻] − [HCO₃⁻]
- Normal ≤ 12–14 mmol/L (depending on lab; some use ≤ 12 with albumin correction)
- RTA = Normal AG (NAGMA) — the hallmark
Worked example from teaching clinic [7]:
Na⁺ = 137, Cl⁻ = 110, HCO₃⁻ = 16 → AG = 137 − 110 − 16 = 11 mmol/L (normal). This confirms NAGMA. Possible causes: GI loss or RTA.
Another example [7]:
Na⁺ = 140, Cl⁻ = 118, HCO₃⁻ = 10.2 → AG = 140 − 118 − 10.2 = 11.8 mmol/L (normal). Again NAGMA — combined with hypokalaemia, nephrocalcinosis → Type 1 RTA.
High Yield Exam Approach
When you see hyperchloraemia + normal Na⁺ + low HCO₃⁻ on a data interpretation question, your reflex should be: "This is NAGMA — is this GI loss or RTA?" The chloride rises to compensate for bicarbonate loss, maintaining electroneutrality [1].
Investigation: Serum creatinine + eGFR
- The purpose is to distinguish RTA (preserved GFR) from uraemic acidosis of CKD (severely reduced GFR)
- RTA is a hyperchloraemic metabolic acidosis with normal anion gap caused by renal tubular dysfunction in the presence of a relatively normal GFR [16]
- If eGFR < 15–20 mL/min, the acidosis is likely explained by the CKD itself (reduced nephron mass → reduced total NH₃ production → high AG eventually develops), and you should not label it RTA
Why does CKD acidosis have a high AG but RTA has a normal AG? In CKD, the massively reduced nephron count means the kidneys cannot excrete the anions produced by daily acid metabolism (sulphate, phosphate, organic acids) → these unmeasured anions accumulate in the blood → raised AG. In RTA, nephron number is preserved and each nephron can still excrete anions normally — the defect is specifically in H⁺/HCO₃⁻ handling, so anions don't accumulate and the AG stays normal [5].
Investigation: Spot urine Na⁺, K⁺, Cl⁻ (and urine osmolality)
UAG = Urine [Na⁺] + Urine [K⁺] − Urine [Cl⁻] [3][5]
| UAG Result | Interpretation | Mechanism |
|---|---|---|
| Negative | ↑ NH₄⁺ excretion → appropriate renal response | NH₄⁺ is excreted with Cl⁻; more NH₄⁺ = more Cl⁻ = Cl⁻ > Na⁺+K⁺ → negative UAG |
| Positive | ↓ NH₄⁺ excretion → impaired renal acidification | Less NH₄⁺ = less Cl⁻ = Na⁺+K⁺ > Cl⁻ → positive UAG |
UAG should be negative in acidosis; positive indicates decreased NH₄⁺ excretion [3]
Urine Osmolar Gap (UOG) — a more accurate indirect measure of NH₄⁺ [5]:
- UOG = Measured urine osmolality − [2(Urine Na⁺ + Urine K⁺) + Urine urea + Urine glucose]
- Normal UOG > 30; abnormal indicates decreased NH₄⁺ excretion [3]
- Especially useful when UAG is unreliable (e.g., presence of unmeasured anions like hippurate in toluene ingestion, or ketoanions in DKA)
Worked example from teaching clinic [7]:
Urine Na⁺ = 81, Urine K⁺ = 14, Urine Cl⁻ = 72 → UAG = 81 + 14 − 72 = +23 mmol/L (positive) → confirms impaired NH₄⁺ excretion → RTA
Investigation: Serum K⁺ (from RFT) + paired spot urine K⁺
This is the single most important branching point for subtyping:
| Serum K⁺ | RTA Type | Why |
|---|---|---|
| ↓↓ (severe hypoK) | Type 1 (Distal) | H⁺ cannot be secreted → K⁺ must bear entire electrical burden of Na⁺ reabsorption |
| ↓ (mild hypoK) | Type 2 (Proximal) | Secondary hyperaldosteronism from modest hypovolaemia → modest K⁺ wasting |
| ↑ (hyperK) | Type 4 | Aldosterone deficiency/resistance → impaired K⁺ secretion |
Hypokalemic RTA: Type 1, 2, 3. Hyperkalemic RTA: Type 4 [1]
Paired spot urine K⁺ helps confirm renal K⁺ wasting [10][11]:
Investigation: Fresh random morning urine pH (measured with pH electrode, NOT dipstick alone)
Urine dipstick can be used for screening of urine pH but is unreliable. Formal measurement of urine pH should be performed with pH electrode using fresh random morning urine sample [16]
| Urine pH (untreated) | Interpretation | Type |
|---|---|---|
| > 5.5 (always, even in severe acidosis) | Cannot secrete H⁺ → cannot acidify urine | Type 1 (Distal) [1][3] |
| < 5.5 (at steady state, without alkali Tx) | Distal acidification intact; problem is proximal HCO₃⁻ reclamation | Type 2 (Proximal) [1][5] |
| < 5.5 | H⁺-ATPase functional but suboptimal | Type 4 [3] |
Inappropriate alkalinuria with systemic acidaemia indicates renal tubular acidosis [17]
The Urine pH Subtlety in Type 2 RTA
A common exam mistake is saying "Type 2 RTA has alkaline urine." This is only true when alkali therapy is being given (pushing plasma HCO₃⁻ above the lowered Tm). Without bicarbonate treatment, plasma HCO₃⁻ = Tm → urinary bicarbonate is NOT excreted + distal nephron functions normally to acidify urine → urine pH usually ≤ 5.3 [5]. With treatment, urine pH rises > 6. This variability is a key differentiator from Type 1 (which is always > 5.5) [5].
Confirmatory and Specific Investigations
Once the above stepwise approach has narrowed the diagnosis to a specific type, confirmatory tests establish it definitively and aetiological investigations identify the underlying cause.
For Type 1 (Distal) RTA
- Aim: To test whether the distal nephron can mount an appropriate acidification response when challenged with an exogenous acid load
- Process: Oral NH₄Cl 0.1 g/kg body weight
- NH₄Cl is metabolised in the liver → generates HCl → systemic acid load
- Expected findings:
Why does this work? You are artificially creating an acid load that the kidney must handle. If the distal H⁺-ATPase is broken (Type 1), no matter how much acid you load, the urine pH cannot drop below 5.5–6.0. This is the definitive proof that the distal acidification machinery is defective.
| Investigation | Finding | Rationale |
|---|---|---|
| KUB X-ray / Renal USS | Nephrocalcinosis, renal stones [3] | Calcium phosphate deposits due to hypercalciuria + alkaline urine + hypocitraturia |
| 24-hr urine calcium | ↑ Hypercalciuria | Acidosis-induced bone dissolution + reduced tubular Ca²⁺ reabsorption |
| Urine citrate | ↓ Hypocitraturia | Acidosis promotes proximal citrate reabsorption; low citrate → reduced inhibition of crystallisation |
| Autoimmune screen | ANA, anti-Ro/La (SSA/SSB), dsDNA, RF | Sjögren syndrome, SLE, RA [1] — must screen in every case of distal RTA |
| Schirmer test / salivary gland biopsy | Dry eyes/mouth | If Sjögren's suspected |
| Serum calcium, PTH | ↑ Ca²⁺, ↑ PTH | Primary hyperparathyroidism → hypercalcaemia → nephrocalcinosis → Type 1 RTA |
| Drug history | Amphotericin B, lithium, ifosfamide, toluene | Drug-induced causes |
| Audiometry | Sensorineural hearing loss | Inherited H⁺-ATPase mutations (ATP6V1B1) |
For Type 2 (Proximal) RTA
- Aim: To test whether the proximal tubule can reabsorb a bicarbonate load (i.e., measure the fractional excretion of HCO₃⁻)
- Process: IV sodium bicarbonate 4.2% infusion at 1–2 mmol/kg/hour until serum HCO₃⁻ > 22 mmol/L and urine pH > 7.5 [7]
- Calculation:
FEHCO₃⁻ = (Urine HCO₃⁻ × Plasma Creatinine) / (Plasma HCO₃⁻ × Urine Creatinine) × 100%
- Expected findings:
Worked example from teaching clinic [7]:
Serum HCO₃⁻ = 26, Serum Cr = 42, Urine HCO₃⁻ = 82.1, Urine Cr = 605 FEHCO₃⁻ = (82.1 × 42) / (26 × 605) × 100% = 3448.2 / 15730 × 100% = 21.9% (> 15%) → diagnosis of proximal RTA confirmed [7]
Why does this work? At steady state (without bicarbonate infusion), the plasma HCO₃⁻ has already fallen to the new, lower Tm and there is minimal bicarbonaturia. The test forces plasma HCO₃⁻ above the defective threshold — now the leaky proximal tubule cannot reabsorb the excess, and bicarbonate pours into the urine.
If Type 2 RTA is confirmed, you must evaluate for generalised proximal tubular dysfunction (Fanconi syndrome) [7][16]:
| Investigation | Finding | Significance |
|---|---|---|
| Urine glucose + fasting blood glucose | Glycosuria with normal fasting glucose (e.g., urine glucose 4+, FBG 4.4 mmol/L) [7] | Renal glycosuria — glucose leaks because PCT reabsorption is defective, NOT because blood glucose is high. Glycosuria does not occur until plasma glucose > 10 mmol/L in normal kidney function [18] |
| Urine amino acids | Generalised aminoaciduria [7] | PCT cannot reabsorb amino acids |
| Urine β2-microglobulin | Markedly elevated (e.g., 38.5 μg/mL; normal < 0.2 μg/mL) [7] | Low molecular weight (tubular) proteinuria — β2-microglobulin is freely filtered and normally completely reabsorbed by PCT |
| Serum phosphate + TRP% | Hypophosphataemia; TRP% < 85% (e.g., 42%) [7] | Phosphate wasting → confirms renal phosphate loss (normal TRP > 85%) |
| Serum uric acid | ↓ Hypouricaemia with hyperuricosuria | Urate wasting through PCT |
| TTKG | > 4 confirms renal K⁺ loss (e.g., TTKG = 5.7) [7] | Confirms the hypokalaemia is of renal origin |
Fanconi Syndrome Features — Exam Checklist
Fanconi syndrome = generalised proximal tubular dysfunction → [16]
- Excessive excretion of K⁺ (hypokalaemia), Ca²⁺ (hypercalciuria), PO₄³⁻ (hypophosphataemia), uric acid (hypouricaemia), glucose (glycosuria), amino acids (generalised aminoaciduria), and β2-microglobulin (tubular proteinuria)
| Investigation | Target Cause |
|---|---|
| Drug history (TDF, cisplatin, ifosfamide, heavy metals) | Drug-induced Fanconi [4] |
| SPEP/UPEP + serum free light chains | Monoclonal gammopathy / myeloma [3] |
| Slit lamp (Kayser-Fleischer rings), serum caeruloplasmin, 24-hr urine copper | Wilson's disease |
| White cell cystine levels | Cystinosis (children) |
| Galactose-1-phosphate uridylyltransferase | Galactosaemia |
For Type 4 (Hyperkalaemic) RTA
- TTKG = (Urine K⁺ / Plasma K⁺) / (Urine Osm / Plasma Osm)
- TTKG < 7 suggests aldosterone deficiency or resistance [3] — because aldosterone normally drives a TTKG of > 7 by stimulating K⁺ secretion
| Investigation | Finding | Interpretation |
|---|---|---|
| Plasma renin activity (PRA) | Low | Hyporeninaemic state (diabetic nephropathy) |
| Serum aldosterone | Low (with low renin) | Hyporeninaemic hypoaldosteronism — the single most common cause |
| Serum aldosterone | Low (with high renin) | Primary adrenal insufficiency (Addison's) |
| Serum aldosterone | Normal/high (with high renin) | Aldosterone resistance (pseudohypoaldosteronism, CNI, K⁺-sparing diuretics) |
| Serum cortisol + ACTH stimulation test | Low cortisol, poor response | Addison's disease |
| HbA1c, glucose | Elevated | Diabetes — underlying diabetic nephropathy |
| Drug history | ACEi, ARB, spironolactone, trimethoprim, heparin, CNI | Drug-induced Type 4 RTA |
| Modality | Findings | Relevance |
|---|---|---|
| KUB X-ray | Nephrocalcinosis (medullary calcification), radio-opaque renal stones | Type 1 RTA — calcium phosphate stones are radio-opaque |
| Renal USS | Bilateral medullary nephrocalcinosis; assess kidney size, exclude obstruction | First-line imaging; also excludes obstructive uropathy as cause of Type 4 RTA |
| CT KUB (non-contrast) | More sensitive for stones and nephrocalcinosis | If KUB/USS inconclusive. In the presence of renal impairment, try avoiding contrast CT to prevent toxicity [19] |
| DEXA scan | Reduced bone mineral density | Osteomalacia/rickets from chronic acidosis ± phosphate wasting (Types 1 and 2) |
| Test | What It Confirms | Key Threshold | Type |
|---|---|---|---|
| NH₄Cl loading test | Distal acidification defect | Urine pH remains > 5.5–6.0 | Type 1 [3][5] |
| Bicarbonate loading test (FEHCO₃⁻) | Proximal HCO₃⁻ wasting | FEHCO₃⁻ > 15% | Type 2 [3][5][7] |
| TTKG | Aldosterone deficiency/resistance | < 7 | Type 4 [3] |
| UAG | Impaired renal NH₄⁺ excretion | Positive | All types |
| UOG | Impaired renal NH₄⁺ excretion | < 30 | All types |
| Urine pH | Failure of urinary acidification | > 5.5 in acidaemia | Type 1 (constant); Type 2 (only with alkali Tx) |
Here is how the algorithm plays out in a typical exam scenario:
Scenario: 17-year-old male, presented in neonatal period with vomiting and poor weight gain. Bloods: K⁺ 2.8 mmol/L, Cl⁻ 118 mmol/L, HCO₃⁻ 10.2 mmol/L, pH 7.17, pCO₂ 4.4 kPa. USS: bilateral medullary nephrocalcinosis. [7]
- Step 1: pH 7.17, HCO₃⁻ 10.2, pCO₂ low → metabolic acidosis ✓
- Step 2: AG = 140 − 118 − 10.2 = 11.8 (normal) → NAGMA ✓
- Step 3: Creatinine 33 μmol/L → GFR preserved ✓
- Step 4: UAG = 81 + 14 − 72 = +23 (positive) → impaired NH₄⁺ excretion → RTA ✓
- Step 5: K⁺ 2.8 → hypokalaemia → Type 1 or 2
- Step 6: Urine pH > 5.5 + nephrocalcinosis on USS → Type 1 (Distal) RTA ✓
This is a textbook Type 1 RTA case from the HKUMed Nephrology Teaching Clinic [7].
High Yield Summary — Diagnosis of RTA
-
Confirm NAGMA: Low pH + low HCO₃⁻ + hyperchloraemia + normal AG (hint: ↑Cl⁻ with normal Na⁺)
-
Check GFR is preserved — if not, it is CKD acidosis, not RTA
-
UAG is the key pivot: positive = RTA, negative = GI loss
-
Serum K⁺ sorts into hypokalaemic RTA (Types 1/2) vs hyperkalaemic RTA (Type 4)
-
Urine pH differentiates Type 1 (always > 5.5) from Type 2 (< 5.5 untreated)
-
Confirmatory tests: NH₄Cl loading (Type 1), FEHCO₃⁻ > 15% (Type 2), TTKG < 7 + renin/aldo (Type 4)
-
Always search for Fanconi features if Type 2 is suspected (glycosuria, aminoaciduria, tubular proteinuria, hypoPO₄)
-
Always screen for autoimmune disease if Type 1 is suspected (Sjögren, SLE)
-
Always review drug history for all types (TDF, amphotericin B, ACEi/ARB, lithium, CNI)
Active Recall - Diagnosis and Investigations of RTA
References
[1] Senior notes: Block A - Electrolyte and Acid-Base Disorders.pdf (Renal Tubular Acidosis section) [2] Senior notes: Block A – Nephrology Data Interpretation.pdf (RTA definition, Type 4 RTA and DM) [3] Senior notes: Maksim Medicine Notes.pdf (p214, RTA comparison table) [4] Senior notes: Block A - I am a hepatitis B carrier.pdf (TDF vs TAF, Fanconi syndrome) [5] Senior notes: Ryan Ho Urogenital.pdf (p41–44, RTA workup, FEHCO₃⁻, NH₄Cl loading, comparison table) [7] Senior notes: Block A - Nephrotology Teaching Clinic RTD.pdf (Fanconi syndrome case, Distal RTA case, bicarbonate loading test worked example, UAG calculation) [9] Lecture slides: Introduction-kidney-Ix.pdf / Nephrology - ntroduction to Renal Investigation.pdf (p29, When to suspect renal tubular problems) [10] Senior notes: Ryan Ho Chemical Path.pdf (p18, Hypokalaemia workup with paired urine K) [11] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p60, Diagnostic algorithm for hypokalaemia) [12] Lecture slides: GC 044. Electrolyte and Acid-Base Disorders.pdf (p25, RTA Diagnosis slide) [16] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p1035–1040, RTA overview, classification, diagnosis) [17] Senior notes: Ryan Ho Fundamentals.pdf (p477, Urine pH interpretation — inappropriate alkalinuria) [18] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p417, Urine glucose and glycosuria threshold) [19] Senior notes: Block A - Two cases of polyuria and polydipsia.pdf (Avoiding contrast CT in renal impairment)
Management of Renal Tubular Acidosis
The management of RTA follows three universal pillars, applied to every type:
- Identify and treat the underlying cause — this is paramount; the RTA is often a manifestation of something else
- Correct the metabolic acidosis — usually with alkali therapy (oral bicarbonate or citrate salts)
- Correct electrolyte disturbances — potassium (replace if low, reduce if high), phosphate, calcium, and volume status
The specific drugs, doses, and nuances differ dramatically between types because the pathophysiology is fundamentally different. What helps Type 1 can actually harm Type 2 (the potassium paradox), and what helps Types 1/2 is irrelevant for Type 4 where the entire problem is aldosterone-related.
Type 1 (Distal) RTA — Management
This is always the first step. Many causes of distal RTA are treatable:
- Autoimmune (Sjögren's, SLE): Sjögren's syndrome-induced Type 1 Distal RTA has a specific treatment — steroids [1]. Immunosuppressive therapy (corticosteroids ± hydroxychloroquine or other DMARDs) targets the underlying autoimmune interstitial nephritis. Immune-mediated RTA — patient managed to achieve remission [19]. The RTA may actually resolve with successful autoimmune disease control.
- Drug-induced: Stop the offending agent (amphotericin B, lithium, ifosfamide, toluene)
- Hypercalcaemia: Treat the underlying cause (e.g., primary hyperparathyroidism → parathyroidectomy; sarcoidosis → corticosteroids)
The goal is to buffer the daily acid load that the kidney cannot excrete and replace any ongoing urinary bicarbonate losses.
Drug choices:
| Agent | Dose | Mechanism | Advantages |
|---|---|---|---|
| Oral NaHCO₃ | 1–2 mEq/kg/day [5] | Directly provides bicarbonate to buffer acid load | Simple, cheap, widely available |
| Potassium citrate | 1–2 mEq/kg/day (as citrate equivalents) | Citrate is metabolised by the liver to HCO₃⁻ (each citrate → 3 HCO₃⁻) | Preferred in Type 1 — simultaneously provides K⁺ replacement AND alkali; citrate also inhibits renal stone formation [3] |
Potassium citrate is a better alternative for distal RTA (citrate → HCO₃⁻ by liver) [1]
Why is potassium citrate preferred over NaHCO₃ in Type 1?
- Type 1 RTA patients have severe hypokalaemia → potassium citrate provides both the alkali AND the K⁺ in a single agent
- Citrate is a natural inhibitor of calcium crystallisation in urine → protects against nephrocalcinosis and stone formation, which is a major complication of Type 1 RTA
- NaHCO₃ carries a sodium load (1 mmol Na⁺ per mmol HCO₃⁻) → risk of volume expansion and hypertension [1][5]
Why the dose is relatively low (1–2 mEq/kg/day)?
- In Type 1, the proximal tubule is intact → it can reclaim almost all filtered HCO₃⁻
- You only need to replace the daily acid load that the distal nephron cannot handle (~1 mmol/kg/day in adults)
- Higher doses in children are given to provide buffer for the additional acid load generated by the growing skeleton [5]
Effect of Alkali on Potassium in Type 1 — High Yield
Effect of alkali treatment on K⁺ in Type 1: IMPROVES [3]
- Alkali therapy alkalinises the tubular fluid → this favours H⁺ excretion (by reducing the H⁺ gradient the pump must work against), partially restoring the H⁺/K⁺ balance
- Additionally, correcting acidosis expands ECV → reduces RAAS activation → reduces aldosterone-driven Na⁺ reabsorption → reduces the voltage-dependent K⁺ secretion
- Often reversed by adequate alkali therapy by alkalinisation of tubular fluid (favours H⁺ excretion) [5]
- If hypokalaemia is severe and symptomatic (K⁺ < 3.0, arrhythmias, weakness), replace K⁺ urgently before starting alkali therapy
- Oral KCl or potassium citrate (which serves dual purpose)
- Monitor K⁺ regularly — it should improve with alkali therapy
- Renal USS periodically to monitor for nephrocalcinosis progression
- 24-hour urine: calcium, citrate, oxalate, pH
- Adequate fluid intake (> 2L/day) to dilute urine and reduce crystallisation risk
- Potassium citrate itself is therapeutic for stone prevention
- Chronic acidosis → bone buffering → osteomalacia/rickets
- Correcting acidosis with alkali therapy is the primary treatment for bone disease
- Vitamin D and calcium supplementation if deficient
- Monitor ALP, calcium, phosphate, PTH
Type 2 (Proximal) RTA — Management
This is even more critical in Type 2 because the RTA is almost always secondary to an identifiable cause:
- Drug-induced Fanconi: Stop TDF and switch to TAF [4]. TAF is the prodrug of tenofovir → lower circulating TFV levels (> 90% reduction) → less proximal tubular toxicity [4]. Similarly, stop ifosfamide, cisplatin, or remove heavy metal exposure.
- Myeloma/monoclonal gammopathy: Treat the underlying haematological malignancy (chemotherapy, stem cell transplant)
- Inherited IEM: Specific treatments where available (e.g., cysteamine for cystinosis, dietary restriction for galactosaemia)
Treatment mainly consists of replacement of substances lost in the urine (mainly fluid and bicarbonate) [7]
Type 2 RTA requires dramatically higher doses of bicarbonate compared to Type 1:
| Agent | Dose | Why so high? |
|---|---|---|
| Oral NaHCO₃ | 10–15 mEq/kg/day [5] | Because any increase in plasma HCO₃⁻ above the lowered Tm is immediately dumped into the urine. You are fighting a losing battle — every mmol of HCO₃⁻ you give that raises plasma HCO₃⁻ above the Tm is wasted in the urine. You need massive doses just to maintain a slightly higher steady-state HCO₃⁻ [5] |
Bicarbonate requirement is higher in proximal RTA despite less marked metabolic acidosis. This is because any increase in bicarbonate concentration in blood would lead to increased bicarbonate excretion (> Tm), thus jeopardising efficacy of bicarbonate Tx [5]
Very high dose is required in proximal RTA because of loss of HCO₃⁻ in urine [1]
Why NaHCO₃ rather than potassium citrate in Type 2?
- Potassium citrate can also be used, but the primary concern in Type 2 is the volume of alkali needed — NaHCO₃ is more practical at such high doses
- However, the Na⁺ load is a concern (each mEq of NaHCO₃ carries 1 mEq Na⁺) → risk of volume expansion [1][5]
Effect of Alkali on Potassium in Type 2 — CRITICAL Exam Point
Effect of alkali treatment on K⁺ in Type 2: WORSENS [3]
- Increased distal Na⁺ delivery causes increased K⁺ secretion [3]
- When you give bicarbonate, you push plasma HCO₃⁻ above the Tm → massive bicarbonaturia → Na⁺ is co-excreted with HCO₃⁻ (Na-HCO₃⁻ cotransporter) → increased Na⁺ and HCO₃⁻ delivery to the distal nephron → increased Na⁺ reabsorption via ENaC → increased lumen-negative voltage → drives K⁺ secretion → worsening hypokalaemia
- Additionally, HCO₃⁻ is an impermeant anion in the distal nephron → enhances the electrical driving force for K⁺ secretion
This means you MUST co-administer potassium aggressively when giving bicarbonate in Type 2 RTA.
- K⁺ supplement — e.g., potassium citrate [3]
- Must be given concurrently with alkali therapy to prevent dangerous hypokalaemia
- Some clinicians use potassium citrate as the primary alkali agent in Type 2 as well (serves dual purpose), but the volumes needed are large
If the patient has generalised proximal tubular dysfunction (Fanconi syndrome), you must replace everything the proximal tubule is wasting:
| Substance Lost | Replacement | Rationale |
|---|---|---|
| Phosphate | Oral phosphate supplements (e.g., Joulie's solution, K-Phos) | Prevent hypophosphataemic rickets/osteomalacia |
| Vitamin D | Calcitriol (1,25-dihydroxyvitamin D₃) | The proximal tubule is the site of 1α-hydroxylation; if damaged, active vitamin D cannot be produced; also aids phosphate and calcium absorption |
| Fluid | Adequate hydration | Replace polyuria-related losses |
| Amino acids | Generally not supplemented directly | Aminoaciduria rarely causes clinical deficiency in isolation |
| Glucose | Not needed | Renal glycosuria alone does not cause hypoglycaemia |
Most essential in children to prevent growth stunting due to bone disease [5]
- In refractory cases, thiazide diuretics (e.g., hydrochlorothiazide) can be used as adjunct therapy
- Why? Thiazides induce mild volume contraction → stimulate proximal tubular Na⁺ (and therefore HCO₃⁻) reabsorption → effectively raises the functional Tm and reduces bicarbonaturia
- Also reduces the dose of exogenous bicarbonate needed
- Caution: thiazides themselves cause hypokalaemia, so potassium must be monitored even more closely
- Acetazolamide (Diamox) is a carbonic anhydrase inhibitor that specifically worsens proximal RTA by further inhibiting proximal HCO₃⁻ reabsorption
- RFT must be checked before using systemic acetazolamide as it may precipitate metabolic acidosis in a patient with poor renal function [20]
- This is a drug contraindication to remember
Type 4 (Hyperkalaemic) RTA — Management
Type 4 is fundamentally different — the problem is aldosterone deficiency or resistance, leading to hyperkalaemia and (secondarily) acidosis. The management priorities are therefore reversed: treat the hyperkalaemia first, then address the acidosis.
Stop ACEi/ARB [3] — this is the single most common and easily reversible cause of Type 4 RTA in clinical practice. Also consider:
- Stopping potassium-sparing diuretics (spironolactone, eplerenone, amiloride)
- Reducing or stopping calcineurin inhibitors (cyclosporine, tacrolimus) if possible
- Stopping trimethoprim (which blocks ENaC like amiloride)
- Stopping heparin (which inhibits aldosterone synthesis)
In a diabetic patient on ACEi with persistent hyperK and mild acidosis, the first step is often to switch ACEi to another antihypertensive class that does not affect the RAAS (e.g., calcium channel blocker)
Hyperkalemia is a hallmark for Type 4 RTA [1]
| Modality | Mechanism | Details |
|---|---|---|
| Low K⁺ diet | Reduce intake | Avoid bananas, oranges, potatoes, tomatoes, chocolate |
| Loop diuretics | Excrete K⁺ — promote urinary K⁺ loss [1][3] | Furosemide/frusemide increases distal Na⁺ delivery → increases K⁺ secretion. Also has mild volume-depleting effect which can be beneficial |
| Oral potassium binders | Bind K⁺ in the GI tract → faecal excretion | Patiromer (onset 4–7 hours), Sodium zirconium cyclosilicate (onset 2h), Sodium polystyrene sulfonate (SPS) [21] |
Potassium Binders — Important Details
Oral potassium binders are for long-term control, NOT acute management of hyperkalaemia [21]. For acute hyperK with ECG changes, use the standard emergency protocol: IV calcium gluconate (membrane stabilisation) → insulin-dextrose drip (transcellular K⁺ shift) → inhaled beta-2 agonist → oral resonium C [21][22]
Sodium polystyrene sulfonate (SPS) has the rare but serious side effect of colonic necrosis [21]. The newer agents (patiromer, sodium zirconium cyclosilicate) are better tolerated and preferred.
- Fludrocortisone (9α-fluorohydrocortisone) is a synthetic mineralocorticoid
- Fludrocortisone [3] — indicated when there is true aldosterone deficiency (not resistance)
- Particularly useful in Addison's disease, congenital adrenal hyperplasia, and selected cases of hyporeninaemic hypoaldosteronism
- Dose: 0.05–0.2 mg/day orally
- Mechanism: Replaces the absent aldosterone → stimulates ENaC-mediated Na⁺ reabsorption and K⁺/H⁺ secretion → corrects both hyperkalaemia and acidosis
Contraindications/Cautions:
- Hypertension: fludrocortisone causes sodium and water retention → can worsen or cause hypertension
- Heart failure: volume expansion from Na⁺ retention
- Oedema: same mechanism
- Not useful in aldosterone resistance (e.g., CNI-induced, pseudohypoaldosteronism) — the receptors/channels are the problem, not the hormone
- ± NaHCO₃ [3] — used if acidosis persists after correcting hyperkalaemia and treating the underlying cause
- Dose is modest (1–2 mEq/kg/day) since the acidosis is typically mild (HCO₃⁻ 17–22)
- Caution with the Na⁺ load — especially in patients with concurrent CKD, HF, or hypertension
- Correcting the hyperkalaemia itself often improves the acidosis (because normal K⁺ restores ammoniagenesis)
Since bicarbonate is used across all types, understanding its risks is critical [1][5]:
| Risk | Mechanism | Clinical Relevance |
|---|---|---|
| Induce hypokalaemia | Shifts K⁺ intracellularly; particularly in patients with existing hypokalaemia or normoK with K⁺ deficit (e.g., DKA) [1] | Must check and replace K⁺ before giving NaHCO₃, especially in Types 1 and 2 |
| Decrease ionic calcium | Alkalosis frees up albumin binding sites for Ca²⁺ → more Ca²⁺ bound → less ionised Ca²⁺. Problem in CRF with pre-existing hypocalcaemia [1] | Risk of tetany, arrhythmia |
| Volume expansion from Na⁺ load | 1 mmol HCO₃⁻ carries 1 mmol Na⁺. 200 mmol NaHCO₃ = more than 1L normal saline (154 mmol Na⁺) [1] | Risk of hypertension, oedema, heart failure |
| Paradoxical cerebral acidosis | Bicarbonate breaks down to CO₂ in blood → CO₂ crosses BBB freely → carbonic anhydrase converts CO₂ + H₂O → H₂CO₃ → H⁺ in CSF [1] | Too-rapid correction can worsen CNS symptoms; correct slowly |
| Feature | Type 1 (Distal) | Type 2 (Proximal) | Type 4 (Hyperkalaemic) |
|---|---|---|---|
| Treat underlying cause | Stop drug, steroids for Sjögren's/SLE | Stop TDF→switch TAF, treat myeloma, treat IEM | Stop ACEi/ARB [3], stop K-sparing diuretics |
| Alkali agent of choice | Potassium citrate (preferred) or NaHCO₃ [1][3] | Oral NaHCO₃ [3] | ± NaHCO₃ (low dose, if needed) [3] |
| Alkali dose | Low: 1–2 mEq/kg/day [5] | High: 10–15 mEq/kg/day [5] | Low: 1–2 mEq/kg/day (if used) |
| Effect of alkali on K⁺ | Improves [3] | Worsens [3] | N/A (hyperK is the problem) |
| K⁺ management | K⁺ replacement (citrate preferred) | Aggressive K⁺ replacement alongside alkali [3] | Low K diet, loop diuretics, K binders [1][3] |
| Other medications | — | Thiazide (adjunct), phosphate/Vit D if Fanconi | Fludrocortisone (if aldo deficiency) [3] |
| Monitoring | Renal USS for stones, autoimmune markers | Electrolytes (esp K⁺), phosphate, bone health | K⁺, renal function, BP |
Special Situations
- Most essential in children to prevent growth stunting due to bone disease [5]
- Higher alkali doses may be needed in children due to the additional acid load from skeletal growth
- Type 1 RTA in infants: growth failure and vomiting may be the presenting complaints → early diagnosis and alkali therapy can normalise growth velocity
- Fanconi syndrome in children (e.g., cystinosis): aggressive phosphate and calcitriol supplementation is critical to prevent rickets
- Alkali therapy should be continued/initiated if needed — metabolic acidosis is harmful to the foetus
- Potassium citrate is generally safe in pregnancy
- For Type 4: fludrocortisone can be used cautiously; ACEi/ARBs are absolutely contraindicated in pregnancy (teratogenic — renal agenesis, oligohydramnios)
- Lithium causes nephrogenic DI, CKD (chronic tubulointerstitial nephropathy), and incomplete distal RTA [23]
- Management: discuss with psychiatrist about switching to an alternative mood stabiliser; if lithium must continue, amiloride paradoxically can be used to block lithium entry into collecting duct cells via ENaC (lithium enters through the same channel)
- Monitor renal function (eGFR every 6 months) and electrolytes
High Yield Summary — Management of RTA
-
Always treat the underlying cause first — drug-induced RTA may resolve completely with drug cessation
-
Type 1: Potassium citrate is preferred (provides alkali + K⁺ + stone protection). Low dose needed (1–2 mEq/kg/day). Alkali improves K⁺. Steroids for Sjögren's-induced Type 1 [1]
-
Type 2: NaHCO₃ at HIGH doses (10–15 mEq/kg/day) because of urinary HCO₃⁻ wasting above lowered Tm. Alkali worsens K⁺ → must co-supplement K⁺ aggressively. Replace phosphate and Vit D if Fanconi. Switch TDF to TAF [4]
-
Type 4: Stop ACEi/ARB. Treat hyperK with low K diet + loop diuretics + K binders. Fludrocortisone if true aldosterone deficiency. ± NaHCO₃ [3]
-
NaHCO₃ risks: hypokalaemia (transcellular shift), decreased ionic Ca²⁺, Na⁺ volume overload, paradoxical cerebral acidosis [1]
-
Alkali on K⁺: Type 1 = improves; Type 2 = worsens — this is a favourite exam question [3]
Active Recall - Management of RTA
References
[1] Senior notes: Block A - Electrolyte and Acid-Base Disorders.pdf (Management of RTA, Risks of NaHCO₃) [3] Senior notes: Maksim Medicine Notes.pdf (p214, RTA management table, effect of alkali on K⁺) [4] Senior notes: Block A - I am a hepatitis B carrier.pdf (TDF vs TAF, Fanconi syndrome) [5] Senior notes: Ryan Ho Urogenital.pdf (p42–44, RTA management, bicarbonate dosing, alkali–potassium interaction) [7] Senior notes: Block A - Nephrotology Teaching Clinic RTD.pdf (Fanconi syndrome treatment) [19] Senior notes: Block A - Two cases of polyuria and polydipsia.pdf (Autoimmune RTA remission) [20] Senior notes: Ryan Ho Opthalmology.pdf (Acetazolamide contraindication in renal impairment) [21] Senior notes: Block A - Chronic Kidney Disease and its Complications.pdf (Potassium binders, SPS colonic necrosis) [22] Senior notes: Ryan Ho Critical Care.pdf (Acute hyperK management protocol) [23] Senior notes: Ryan Ho Psychiatry.pdf (Lithium renal side effects including incomplete distal RTA)
Complications of Renal Tubular Acidosis
The complications of RTA arise from two fundamental, interacting processes: (1) the chronic metabolic acidosis itself, and (2) the specific electrolyte disturbances particular to each type. Most complications develop insidiously over months to years if the RTA is not recognised and treated. Think of RTA as a slow-burning metabolic fire — the patient may not feel acutely unwell, but the body is silently cannibalising its own skeleton, stressing its cardiovascular system, and damaging its kidneys.
Primarily affects: Type 1 (Distal) RTA
This is one of the most clinically significant and exam-relevant complications. Renal stones and nephrocalcinosis are common in Type 1 RTA [3].
Pathophysiology — a "triple hit":
Acidosis causes: [1]
- Increased calcium resorption from bone — chronic acidosis promotes bone mineral dissolution as the skeleton buffers excess H⁺ ions. The hydroxyapatite [Ca₁₀(PO₄)₆(OH)₂] in bone acts as a buffer, releasing Ca²⁺ and PO₄³⁻ into the circulation → hypercalciuria
- Reduced tubular Ca²⁺/PO₄ reabsorption — acidosis directly inhibits calcium reabsorption in the distal nephron → even more calcium dumped into the urine
- Results in hypercalciuria → formation of nephrocalcinosis/stones [1]
Additionally:
- ↑ urine pH → ↓ solubility of Ca and PO₄ [3] — calcium phosphate is far less soluble at alkaline pH. Since Type 1 RTA patients have urine pH persistently > 5.5–6.0, the calcium and phosphate in the urine precipitate readily
- ↓ CaPO₄ reabsorption in renal tubules [3]
- Hypocitraturia — citrate is a natural chelator of calcium in urine, preventing crystallisation. In metabolic acidosis, the proximal tubule avidly reabsorbs citrate (citrate metabolism is stimulated by intracellular acidosis) → less citrate reaches the urine → reduced protection against stone formation
The combination of hypercalciuria + alkaline urine + hypocitraturia creates a perfect storm for calcium phosphate precipitation in the renal medulla (nephrocalcinosis) and collecting system (stones).
Clinical significance:
- Nephrocalcinosis can itself cause further tubular damage → worsening RTA → vicious cycle
- Renal stones cause recurrent colic, haematuria, urinary obstruction, and recurrent UTIs
- Chronic obstruction and infection can lead to progressive CKD
Why Type 2 (Proximal) RTA is protected: Proximal RTA → the hypercitraturia prevents the formation of renal stones [1]. In proximal RTA, the defective PCT cannot reabsorb citrate (just as it cannot reabsorb bicarbonate, phosphate, etc.) → citrate spills into the urine → more urinary citrate → greater protection against crystallisation. Additionally, the urine pH is not persistently alkaline at steady state, removing another risk factor.
Nephrocalcinosis: Type 1 vs Type 2 — Favourite Exam Question
Presence or absence of renal stones can differentiate proximal and distal RTA [1]:
- Type 1: Stones/nephrocalcinosis common (hypercalciuria + alkaline urine + hypocitraturia)
- Type 2: Stones rare (hypercitraturia + urine not persistently alkaline)
Primarily affects: Types 1 and 2
Bone diseases are common due to acidosis → ↑ bone breakdown [5]
Pathophysiology:
Chronic metabolic acidosis damages bone through multiple converging mechanisms:
-
Direct acid buffering by bone: When the blood is chronically acidotic, the skeleton serves as a "buffer reservoir." H⁺ ions are exchanged for Ca²⁺ and Na⁺ at the bone surface → dissolution of hydroxyapatite → bone demineralisation. Over months/years, this leads to clinically significant bone loss.
-
Stimulation of osteoclast activity: Acidosis directly activates osteoclasts (bone-resorbing cells) and inhibits osteoblasts (bone-forming cells). The net effect is increased bone resorption.
-
Phosphate wasting (particularly in Type 2 / Fanconi syndrome): Hypophosphataemia/hyperphosphaturia [7] → phosphate is an essential component of hydroxyapatite. Without adequate phosphate, new bone mineralisation cannot occur → osteomalacia (adults) or rickets (children). This is specifically described as hypophosphataemic rickets (in children) and osteomalacia (in adults) [7].
-
Impaired vitamin D metabolism: In Fanconi syndrome, proximal tubular damage can impair 1α-hydroxylation of 25-hydroxyvitamin D → reduced active calcitriol (1,25-dihydroxyvitamin D₃) → decreased intestinal calcium and phosphate absorption → worsening bone disease.
Clinical manifestations:
- Children: Rickets — poor growth, widened wrists, bowing of legs, rachitic rosary, delayed fontanelle closure, growth failure [6][7]
- Adults: Osteomalacia — bone pain, proximal myopathy, pathological fractures, waddling gait, Looser zones on X-ray
- Both are characterised by elevated ALP (reflecting increased osteoblastic activity attempting to compensate)
Example from teaching clinic [7]: The 17-year-old with Type 1 RTA had ALP of 330 U/L (normal 49–138) — markedly elevated, reflecting chronic bone turnover from years of uncompensated acidosis.
TDF is associated with slightly greater decreases in bone mineral density, greater bone turnover. Hypophosphataemia and osteomalacia secondary to proximal renal tubulopathy can also occur [4] — this is a specific HK-relevant complication given the widespread use of TDF for hepatitis B.
Primarily affects: Types 1 and 2 in children
Poor growth is a cardinal feature of childhood RTA [6].
Pathophysiology:
- Chronic metabolic acidosis has a catabolic effect — it promotes protein degradation, inhibits protein synthesis, and impairs the growth hormone/IGF-1 axis
- Metabolic acidosis directly reduces growth hormone secretion and impairs its peripheral action
- Bone disease (rickets) further impairs linear growth
- Anorexia and vomiting from chronic acidosis reduce nutritional intake
- In Fanconi syndrome, loss of amino acids and glucose in the urine represents a chronic nutritional drain
Clinical significance: Early diagnosis and treatment of RTA in children can normalise growth velocity. This is why treatment is most essential in children to prevent growth stunting due to bone disease [5]. Delay in diagnosis of even 1–2 years can result in permanent short stature.
The clinical consequences of hypokalaemia extend beyond simple muscle weakness [24].
Cardiac complications:
- Arrhythmias: Hypokalaemia hyperpolarises the cardiac myocyte resting membrane potential → prolonged repolarisation → prolonged QT interval → predisposes to torsades de pointes (a polymorphic ventricular tachycardia that can degenerate into ventricular fibrillation)
- ECG changes: flattened T waves → U waves → ST depression → widened QRS (in severe cases)
- Fatal arrhythmia [25] is a genuine risk in severe, unrecognised Type 1 RTA
Neuromuscular complications:
- Generalised weakness → especially of the proximal musculature [25] — K⁺ is essential for maintaining the resting membrane potential of skeletal muscle cells. Low extracellular K⁺ hyperpolarises the cell, making it harder to reach the threshold for an action potential → weakness
- Respiratory failure [25] — in severe hypokalaemia, the diaphragm and intercostal muscles can be affected → hypoventilation → respiratory failure
- Paralytic ileus — smooth muscle in the gut is also affected → reduced peristalsis → abdominal distension, constipation, vomiting
- Rhabdomyolysis — severe hypokalaemia impairs muscle blood flow (normally K⁺ is released during exercise to cause local vasodilation; with depleted K⁺ stores this fails → muscle ischaemia → necrosis)
Renal complications of chronic hypokalaemia:
- Impaired urinary concentrating ability leading to polyuria [24] — chronic hypokalaemia downregulates AQP2 (aquaporin-2) water channels in the collecting duct and causes resistance to ADH → nephrogenic diabetes insipidus-like picture → polyuria and polydipsia
- Altered ammonia production [24] — paradoxically, chronic hypokalaemia stimulates proximal ammoniagenesis (because K⁺ and NH₄⁺ compete for transport in the thick ascending limb). In the context of RTA, this creates complex interactions
- Defective urinary acidification [24] — chronic hypokalaemia can itself impair distal H⁺ secretion, potentially worsening the acidosis in a vicious cycle
The mirror image of the above — Type 4 RTA's hallmark complication is hyperkalaemia.
Cardiac complications:
- Hyperkalaemia depolarises the resting membrane potential → reduces the rate of rise of the action potential → widened QRS → eventually sine wave pattern → ventricular fibrillation → cardiac arrest
- ECG progression: peaked T waves → flattened P waves → prolonged PR → widened QRS → sine wave → asystole/VF
- This is immediately life-threatening when K⁺ > 6.5 mmol/L, especially in patients with underlying cardiac disease
Neuromuscular complications:
- Ascending weakness, paraesthesiae
- Unlike hypokalaemia, severe hyperkalaemia can cause flaccid paralysis (depolarisation block)
Affects: All types (if untreated)
Chronic TIN is the major pathway leading to chronic kidney disease [26]
How does RTA lead to CKD?
Several mechanisms contribute:
- Nephrocalcinosis (Type 1): Calcium phosphate deposits in the renal medulla cause chronic tubulointerstitial inflammation and fibrosis → progressive nephron loss → CKD. This creates a vicious cycle: RTA → nephrocalcinosis → CKD → worsening acid handling
- Chronic tubulointerstitial nephritis: Many causes of RTA (Sjögren's syndrome, lithium, heavy metals) involve chronic inflammation of the tubulointerstitium. The tubulointerstitium constitutes 95% of the kidney, so any pathology will have detrimental effects [26]. Ongoing inflammation leads to fibrosis and irreversible nephron loss
- Obstructive nephropathy from recurrent stones (Type 1): Repeated stone episodes → ureteric obstruction → hydronephrosis → pressure-mediated tubular damage → scarring
- Metabolic acidosis itself accelerates CKD progression: Chronic acidosis is associated with increased mortality and faster CKD progression through ↑ bone resorption, ↑ protein catabolism, ↑ secondary hyperPTH [5]. Correcting acidosis with alkali therapy has been shown to slow CKD progression.
Primarily affects: Types 1 and 2
Polyuria, polydipsia and dehydration [7]
Pathophysiology:
- Bicarbonaturia (Type 2) creates an osmotic diuresis (filtered HCO₃⁻ that is not reabsorbed acts as an osmotic solute pulling water with it)
- Chronic hypokalaemia impairs concentrating ability (downregulated AQP2 → nephrogenic DI-like picture)
- Salt depletion and dehydration (↓ Na, water) [6] — the proximal tubule normally reabsorbs ~65% of filtered Na⁺. In Fanconi syndrome, Na⁺ reabsorption is impaired → natriuresis → volume depletion
Clinical significance:
- Volume depletion activates RAAS → secondary hyperaldosteronism → worsens K⁺ wasting
- Dehydration can precipitate pre-renal AKI on top of any existing CKD
- Children are particularly vulnerable to dehydration
Important to recognise that treatment itself can cause complications:
| Complication | Treatment | Mechanism |
|---|---|---|
| Worsening hypokalaemia | NaHCO₃ in Type 2 RTA | Increased distal Na⁺/HCO₃⁻ delivery → increased K⁺ secretion [3] |
| Hypertension / volume overload | NaHCO₃ (any type) | Na⁺ load → fluid retention (200 mmol NaHCO₃ > 1L NS equivalent) |
| Decreased ionised Ca²⁺ | NaHCO₃ overcorrection | Alkalosis exposes albumin Ca²⁺ binding sites → more Ca²⁺ bound → ↓ free ionised Ca²⁺ → tetany |
| Paradoxical cerebral acidosis | Rapid NaHCO₃ infusion | CO₂ crosses BBB freely; HCO₃⁻ does not → CSF pH drops paradoxically |
| Colonic necrosis | Sodium polystyrene sulfonate (SPS/Resonium) for hyperK in Type 4 | Rare but serious; SPS can cause ischaemic mucosal injury, especially with concurrent sorbitol use [21] |
| Hypertension / oedema | Fludrocortisone in Type 4 | Mineralocorticoid effect → Na⁺/water retention |
| Complication | Type 1 | Type 2 | Type 4 |
|---|---|---|---|
| Nephrocalcinosis / stones | +++ (major) | Rare (hypercitraturia protects) | — |
| Rickets / osteomalacia | ++ | +++ (esp. with Fanconi/hypoPO₄) | — |
| Growth failure (children) | ++ | +++ | — |
| Hypokalaemic arrhythmias | +++ (severe hypoK) | + (mild hypoK) | — |
| Muscle weakness / paralysis | ++ | + | + (hyperK → flaccid paralysis) |
| Hyperkalaemic cardiac arrest | — | — | +++ (major) |
| CKD progression | ++ (nephrocalcinosis, TIN) | + (if underlying cause persists) | ++ (DM nephropathy often concurrent) |
| Dehydration / polyuria | + | ++ (bicarbonaturia, Fanconi) | — |
| Recurrent UTIs | ++ (stone-related) | — | — |
High Yield Summary — Complications of RTA
-
Nephrocalcinosis/stones is the signature complication of Type 1 (Distal) RTA — caused by the triple hit of hypercalciuria + alkaline urine + hypocitraturia. Type 2 is protected by hypercitraturia.
-
Bone disease (rickets/osteomalacia) affects both Types 1 and 2 — from chronic acidosis-induced bone buffering + phosphate wasting (especially in Fanconi syndrome).
-
Growth failure in children is a critical complication — early diagnosis and alkali therapy can normalise growth velocity.
-
Hypokalaemia (Types 1, 2) can cause fatal arrhythmias, respiratory failure, rhabdomyolysis, and paralytic ileus. Chronic hypokalaemia also causes nephrogenic DI-like concentrating defect.
-
Hyperkalaemia (Type 4) is immediately life-threatening → cardiac arrest risk when K⁺ > 6.5.
-
CKD can develop from nephrocalcinosis-mediated damage, chronic TIN from the underlying disease, or obstructive nephropathy from recurrent stones.
-
Treatment complications: NaHCO₃ can worsen hypoK in Type 2, cause volume overload, decrease ionised Ca²⁺, or cause paradoxical cerebral acidosis. SPS (Resonium) can cause colonic necrosis.
Active Recall - Complications of RTA
References
[1] Senior notes: Block A - Electrolyte and Acid-Base Disorders.pdf (Distal RTA complications, nephrocalcinosis mechanism) [3] Senior notes: Maksim Medicine Notes.pdf (p214, RTA table — stones, bone disease, effect of alkali on K⁺) [4] Senior notes: Block A - I am a hepatitis B carrier.pdf (TDF bone mineral density loss, osteomalacia) [5] Senior notes: Ryan Ho Urogenital.pdf (p42–44, Bone disease, stones, bicarbonate requirement in children, CKD acidosis consequences) [6] Senior notes: Adrian Lui Pediatrics Notes.pdf (p311, Fanconi syndrome clinical features — rickets, poor growth) [7] Senior notes: Block A - Nephrotology Teaching Clinic RTD.pdf (Fanconi features, Type 1 RTA case with elevated ALP) [21] Senior notes: Block A - Chronic Kidney Disease and its Complications.pdf (SPS colonic necrosis, potassium binders) [24] Senior notes: learning_points_output.txt (Hypokalaemia consequences — cardiac, renal concentrating defect, ammonia) [25] Senior notes: Block A - Two cases of polyuria and polydipsia.pdf (Hypokalaemia complications — weakness, respiratory failure, fatal arrhythmia) [26] Senior notes: Block A - Glomerular and Tubulo-interstitial Diseases and Acute Kidney Injury.pdf (Tubulointerstitium 95%, chronic TIN → CKD)
High Yield Summary
-
RTA = normal anion gap (hyperchloraemic) metabolic acidosis with relatively preserved GFR, caused by specific tubular defects in H⁺ secretion or HCO₃⁻ reclamation
-
Type 1 (Distal): Cannot secrete H⁺ → urine pH always > 5.5 → severe hypokalaemia → nephrocalcinosis/stones (hypercalciuria + hypocitraturia + alkaline urine). Think autoimmune (Sjögren's, SLE), amphotericin B
-
Type 2 (Proximal): Cannot reabsorb HCO₃⁻ → lowered Tm → self-limiting acidosis → urine pH variable (< 5.5 untreated, > 6 with alkali). Often part of Fanconi syndrome. Think TDF, myeloma, cystinosis (kids). Stones rare (hypercitraturia protects)
-
Type 4 (Hyperkalaemic): Aldosterone deficiency/resistance → hyperkalaemia → reduced ammoniagenesis → mild acidosis, urine pH < 5.5. Most common type overall. Think diabetic nephropathy (hyporeninaemic hypoaldosteronism), ACEi/ARB, Addison's
-
Suspect RTA when: hypoK + metabolic acidosis (unusual combination), severe/multiple electrolyte abnormalities, glycosuria without DM, aminoaciduria, or autoimmune disease with electrolyte disturbances
-
Alkali therapy improves K⁺ in Type 1 but worsens K⁺ in Type 2 — know why
-
Nephrocalcinosis differentiates distal from proximal RTA
High Yield Summary — Differential Diagnosis of RTA
-
NAGMA = GI loss vs RTA → Use UAG (negative = GI, positive = RTA) and urine K⁺ to differentiate
-
HypoK + acidosis is unusual → Think RTA Types 1 or 2. HyperK + acidosis → think Type 4 RTA or CKD
-
Urine pH is the single most useful bedside test → > 5.5 always = Type 1; < 5.5 at steady state = Type 2 or Type 4
-
Nephrocalcinosis/stones → strongly favours Type 1 over Type 2
-
Fanconi features (glycosuria, aminoaciduria, hypoPO₄) → Type 2
-
Confirmatory tests: NH₄Cl loading (Type 1), FEHCO₃⁻ > 15% (Type 2), TTKG + renin/aldo (Type 4)
-
Always look for the underlying cause: autoimmune (Types 1, 2), drugs (all types), DM nephropathy (Type 4), IEM (Type 2 in children), myeloma (Type 2 in elderly)
-
Do not confuse with Bartter/Gitelman → these cause metabolic alkalosis, not acidosis
High Yield Summary — Diagnosis of RTA
-
Confirm NAGMA: Low pH + low HCO₃⁻ + hyperchloraemia + normal AG (hint: ↑Cl⁻ with normal Na⁺)
-
Check GFR is preserved — if not, it is CKD acidosis, not RTA
-
UAG is the key pivot: positive = RTA, negative = GI loss
-
Serum K⁺ sorts into hypokalaemic RTA (Types 1/2) vs hyperkalaemic RTA (Type 4)
-
Urine pH differentiates Type 1 (always > 5.5) from Type 2 (< 5.5 untreated)
-
Confirmatory tests: NH₄Cl loading (Type 1), FEHCO₃⁻ > 15% (Type 2), TTKG < 7 + renin/aldo (Type 4)
-
Always search for Fanconi features if Type 2 is suspected (glycosuria, aminoaciduria, tubular proteinuria, hypoPO₄)
-
Always screen for autoimmune disease if Type 1 is suspected (Sjögren, SLE)
-
Always review drug history for all types (TDF, amphotericin B, ACEi/ARB, lithium, CNI)
High Yield Summary — Management of RTA
-
Always treat the underlying cause first — drug-induced RTA may resolve completely with drug cessation
-
Type 1: Potassium citrate is preferred (provides alkali + K⁺ + stone protection). Low dose needed (1–2 mEq/kg/day). Alkali improves K⁺. Steroids for Sjögren's-induced Type 1 [1]
-
Type 2: NaHCO₃ at HIGH doses (10–15 mEq/kg/day) because of urinary HCO₃⁻ wasting above lowered Tm. Alkali worsens K⁺ → must co-supplement K⁺ aggressively. Replace phosphate and Vit D if Fanconi. Switch TDF to TAF [4]
-
Type 4: Stop ACEi/ARB. Treat hyperK with low K diet + loop diuretics + K binders. Fludrocortisone if true aldosterone deficiency. ± NaHCO₃ [3]
-
NaHCO₃ risks: hypokalaemia (transcellular shift), decreased ionic Ca²⁺, Na⁺ volume overload, paradoxical cerebral acidosis [1]
-
Alkali on K⁺: Type 1 = improves; Type 2 = worsens — this is a favourite exam question [3]
High Yield Summary — Complications of RTA
-
Nephrocalcinosis/stones is the signature complication of Type 1 (Distal) RTA — caused by the triple hit of hypercalciuria + alkaline urine + hypocitraturia. Type 2 is protected by hypercitraturia.
-
Bone disease (rickets/osteomalacia) affects both Types 1 and 2 — from chronic acidosis-induced bone buffering + phosphate wasting (especially in Fanconi syndrome).
-
Growth failure in children is a critical complication — early diagnosis and alkali therapy can normalise growth velocity.
-
Hypokalaemia (Types 1, 2) can cause fatal arrhythmias, respiratory failure, rhabdomyolysis, and paralytic ileus. Chronic hypokalaemia also causes nephrogenic DI-like concentrating defect.
-
Hyperkalaemia (Type 4) is immediately life-threatening → cardiac arrest risk when K⁺ > 6.5.
-
CKD can develop from nephrocalcinosis-mediated damage, chronic TIN from the underlying disease, or obstructive nephropathy from recurrent stones.
-
Treatment complications: NaHCO₃ can worsen hypoK in Type 2, cause volume overload, decrease ionised Ca²⁺, or cause paradoxical cerebral acidosis. SPS (Resonium) can cause colonic necrosis.
Metabolic Alkalosis
Metabolic alkalosis is a primary acid-base disorder characterized by an elevated serum bicarbonate concentration and increased arterial pH, often resulting from excessive loss of hydrogen ions or gain of bicarbonate.
Systemic Lupus Erythematosus
Systemic lupus erythematosus is a chronic multisystem autoimmune disorder characterized by the production of autoantibodies (notably anti-dsDNA and anti-Smith) causing widespread inflammation and tissue damage affecting the skin, joints, kidneys, blood cells, and other organs.